New conjugates of montelukast and peptides
By covalently coupling montelukast with a specific amino acid sequence to form a new compound, the problem that existing anti-inflammatory drugs cannot treat inflammation in open wounds is solved, and the anti-inflammatory and wound-healing effects of local administration are achieved.
Patent Information
- Application Number
- CN202310240501.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-12-04
- Filing Date
- 2019-09-14
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2039-09-14
Smart Images

Figure CN116785447B_ABST
Abstract
Description
[0001] The present invention is a divisional application of an invention patent application with an application date of September 14, 2019, application number 2019800043991 (international application number PCT / CN2019 / 105832), and name “New conjugate of montelukast and peptide”. Technical Field
[0002] The present invention relates to novel conjugates of known anti-inflammatory compounds covalently linked to specific peptide sequences, the use of such novel conjugates in human medicine, and pharmaceutical compositions comprising them. In particular, the present invention relates to the use of these conjugates and compositions in the treatment of inflammation. Background Art
[0003] Inflammation is typically characterized as a local tissue response to invasion by, for example, microorganisms, certain antigens, damaged cells, or physical and / or chemical agents. The inflammatory response is generally a protective mechanism for destroying, diluting, or isolating both the noxious agent and the damaged tissue, as well as for initiating tissue healing.
[0004] Inflammation may be caused by physical trauma, infection, some chronic diseases (e.g., psoriasis and autoimmune diseases such as rheumatoid arthritis), and / or a chemical and / or physiological response to external stimuli (e.g., as part of an allergic reaction). A complex series of events may be involved in which inflammatory mediators increase blood flow and dilation of local blood vessels, leading to redness and heat, exudation of fluids, often leading to local swelling, migration of leukocytes into the inflamed area, and pain.
[0005] Many conditions / disorders are characterized by and / or caused by abnormal, tissue damaging inflammation. Such conditions are typically characterized by activation of immune defense mechanisms, resulting in more harmful than beneficial effects on the host, and are often associated with varying degrees of tissue redness or congestion, swelling, hyperthermia, pain, itching, cell death, tissue destruction, cell proliferation, and / or loss of function. Examples include inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis, psoriasis, glomerulonephritis, and transplant rejection.
[0006] Typically, a complex series of events leads to inflammatory changes, such as increased blood flow through local vasodilation, resulting in redness and heat, extravasation of leukocytes and plasma, often leading to local swelling, activation of sensory nerves (causing pain in some tissues), and loss of function. These inflammatory changes are triggered by a cascade of cellular and biochemical events involving cells like neutrophils, monocytes, macrophages, and lymphocytes, as well as inflammatory mediators such as vasoactive amines, cytokines, complement factors, and reactive oxygen species.
[0007] Among other things, inflammation plays a key role in the wound healing process. Therefore, wounds and burns can be classified as conditions associated with inflammation. Conventional wisdom in the art is that anti-inflammatory drugs should not be applied directly to open wounds because this would be detrimental to the progress of wound healing.
[0008] Montelukast is an orally active nonsteroidal immunomodulatory compound that is administered orally to the gastrointestinal tract for maintenance treatment and prevention of seasonal allergy symptoms (see, e.g., Hon et al., Drug Design, Development and Therapy, 8, 839 (2014)). It works primarily by blocking the action of leukotriene D4 (as well as leukotriene C4 and E4) on the cysteinal leukotriene receptor CysLT1 in the airways.
[0009] International patent applications WO 02 / 34237 and WO 2003 / 020200 disclose active agents covalently attached to polypeptides, more particularly homopolymers and heteropolymers of naturally occurring amino acids and / or synthetic amino acids.
[0010] We have previously unexpectedly discovered that montelukast exhibits anti-inflammatory effects when administered topically (e.g., topically), for example, to the skin (see unpublished international patent application PCT / CN 2018 / 094441). We have now discovered that montelukast covalently coupled to certain amino acid sequences produces new compounds that have potential uses in a variety of conditions, including topical treatments of skin conditions such as inflammation and wounds. Summary of the invention
[0011] According to a first aspect of the present invention, there is provided a peptide-containing compound comprising a peptide component, wherein the peptide component is an amino acid sequence of from 2 to 45 amino acids, and the peptide component is covalently bonded to one or more compounds of formula I:
[0012]
[0013] in:
[0014] R 1 is selected from -C(CH3)2OH, -COCH3, -C(CH3)=CH2 and -C(CH3)2H; and
[0015] n is 0, 1, or 2,
[0016] and the regioisomers, stereoisomers, and pharmaceutically or cosmetically acceptable salts of the peptide-containing compounds,
[0017] The peptide-containing compounds, regioisomers, stereoisomers and salts are hereinafter collectively referred to as "compounds of the present invention".
[0018] The compounds of the invention contain at least one primary amide bond through which the one or more compounds of formula I are coupled to the peptide component. The amide bond is formed by reacting one or more carboxylic acid groups in the one or more compounds of formula I with one or more free-NH2 groups in the peptide component. The amide bond can be formed at the N-terminal-NH2 group and / or by one or more other free-NH2 groups in the amino acids present in the peptide sequence.
[0019] Thus, it is preferred that at least one amino acid in the peptide component of the compounds of the invention contains a positively charged group other than the N-terminus (i.e., a free -NH2 group). The amino acids in the peptide component of the compounds of the invention may be naturally occurring (but not necessarily proteinogenic) amino acids and / or synthetic amino acids. Preferably, the amino acids in the peptide component are naturally occurring amino acids.
[0020] For example, at least one amino acid not present at the N-terminus of the peptide component may include asparagine (Asn), more preferably arginine (Arg), and even more preferably lysine (Lys).
[0021] In this regard, it is preferred that at least about 5%, more preferably at least about 10%, such as at least about 15%, including at least about 20% (by number and / or by weight) of the amino acids present in the peptide component comprise such amino acids (i.e., Asn, Arg and / or Lys).
[0022] The peptide component of the compounds of the invention can be a homopolymer of amino acids. Alternatively, the peptide component of the compounds of the invention can be a heteropolymer of two or more different amino acids. Preferably, the peptide component of the compounds of the invention is a heteropolymer of two or more different naturally occurring amino acids (e.g., at least three different amino acids, preferably four different amino acids, most preferably at least five different amino acids).
[0023] Peptide components that may be coupled to the compounds of Formula I include peptides having known antimicrobial and / or anti-inflammatory properties, or fragments or minor variants thereof.
[0024] Fragments of such peptides include "portions" of the full amino acid sequence that may exhibit such antimicrobial and / or anti-inflammatory properties.
[0025] Also included are amino acid sequences that are (e.g., minor) variants of such full amino acid sequences or fragments thereof, which can be synthesized by chemical and / or biological methods (e.g., chemical modification of naturally occurring peptides or by direct synthesis). We mean "(e.g., minor) variants of full amino acid sequences or fragments thereof" as changes in these corresponding sequences that do not negatively affect the essential properties of the relevant full peptides or fragments thereof to a measurable degree.
[0026] Antimicrobial peptides that may be mentioned in this regard include cecropins, such as cecropin A:
[0027] H-Lys-Trp-Lys-Leu-Phe-Lys-Lys-Ile-Glu-Lys-Val-Gly-Gln-Asn-Ile-Arg-Asp-Gly-Ile-Ile-Lys-Ala-Gly-Pro-Ala-Val-Ala-Val-Val-Gly-Gln-Ala-Thr-Gln-Ile-Ala-Lys-NH2 (SEQ ID No:1); Cecropin B:
[0028] and / or
[0029] LL-37:
[0030] H-Leu-Leu-Gly-Asp-Phe-Phe-Arg-Lys-Ser-Lys-Glu-Lys-Ile-Gly-Lys-Glu-Phe-Lys-Arg-Ile-Val-Gln-Arg-Ile-Lys-Asp-Phe-Leu-Arg-Asn-Leu-Val-Pro-Arg-Thr-Glu-Ser-NH2 (SEQ ID No:3).
[0031] Anti-inflammatory peptides that may be mentioned include amino acid sequences that are fragments of mussel adhesion protein (MAP), also known as blue mussel (Mytilus edulis) foot protein (mefp), which is produced by species such as blue mussel, thick shell mussel (Mytilus coruscus) and green mussel (Perna viridis). viridis), including 11 independently identified adhesion protein subtypes from mussels, including collagens pre-COL-P, pre-COL-D, and pre-COL-NG; mussel foot matrix proteins PTMP (proximal silk matrix protein) and DTMP (distal silk matrix protein); and mfp proteins mfp-2 (sometimes referred to as "mefp-2", used interchangeably below), mfp-3 / mefp-3, mfp-4 / mefp-4, mfp-5 / mefp-5, mfp-6 / mefp-6, and most preferably mfp-1 / mefp-1 (see, e.g., Zhu et al., Advances in Marine Science, 32, 560 (2014) and Gao et al., Journal of Anhui Agr. Sci., 39, 19860 (2011)).
[0032] An important part of mefp-1 consists of 70 to 90 tandem repeats of the following decapeptide: Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Lys (SEQ ID No: 4; see Waite, Int. J. Adhesion and Adhesives, 7, 9 (1987)). This decapeptide sequence can be isolated as a low molecular weight derivative of naturally occurring MAP, or can be synthesized, for example, as described by Yamamoto in J. Chem. Soc., Perkin Trans. 1, 613 (1987). See also Dalsin et al., J. Am. Chem. Soc., 125, 4253 (2003).
[0033] In this regard, the peptide component useful in the compounds of the present invention comprises one to four (preferably three, and more preferably two) repeating units of the above-mentioned decapeptide sequence, or most preferably one of the above-mentioned decapeptide sequences, or a variant of any of these options (as defined above).
[0034] Also provided is a peptide-containing compound as defined above, wherein at least about 5%, such as at least about 10% (by number) of the amino acids in the peptide component contain aromatic groups, such as tyrosine and / or 3,4-dihydroxyphenylalanine (DOPA). Alternatively, none of the amino acids in the peptide chain contain aromatic groups, i.e., none of the amino acids are tyrosine and / or DOPA.
[0035] It is further preferred that the peptide component within the compounds of the invention comprises between 5 and 30 amino acids, such as between 6 and 20 amino acids, including between 7 and 15 (e.g. up to 12, such as 10) amino acids in the amino acid sequence.
[0036] Compounds of the invention which may be mentioned in this regard include those in which the peptide component has the following amino acid sequence:
[0037] X-Pro-YZ (SEQ ID No: 5),
[0038] in:
[0039] X represents a chain of 1 to 2 amino acid residues, each of which is independently selected from Ala and Lys;
[0040] Y is selected from Ser and pSer;
[0041] Z represents a chain of 1 (e.g. 2, such as 3) to 7 amino acid residues, each of which is independently selected from Tyr, pTyr, Hyp (i.e., 3Hyp or 4Hyp), Thr, pThr, DOPA and Lys; and
[0042] At least one of said Ala and / or Lys residues is bonded to one or more compounds of formula I, as defined above.
[0043] A specific amino acid sequence that may be mentioned is Ala-Pro-Ser-Hyp-Hyp-Thr (SEQ ID No: 6).
[0044] Preferred compounds of the invention that may be mentioned include those in which the peptide component has the following amino acid sequence:
[0045] G 1 -Lys-Pro-G 2 -T-Hyp-G 3 -Lys (SEQ ID No: 7),
[0046] in:
[0047] G 1 Ala does not exist or represent;
[0048] G 2 Selected from Ser and pSer;
[0049] T is selected from DOPA, or more preferably Tyr and pTyr;
[0050] Hyp is selected from 3Hyp and 4Hyp;
[0051] G3 represents a chain of 1 to 4 (e.g., 1 to 3) amino acid residues, each of which is independently selected from Tyr, pTyr, 3Hyp, 4Hyp, Thr, pThr and DOPA; and
[0052] At least one of said Lys residues and / or said Ala residue when present is bonded to one or more compounds of formula I as defined above.
[0053] Peptide components that may be mentioned include those having the following amino acid sequence:
[0054] Lys-Pro-G 2 -T-Hyp-G 3 -Lys (SEQ ID No: 8),
[0055] Among them G 2 , T, Hyp and G 3 is defined above, where G 2 More preferably, Ser and G 3 More preferred is Tyr or especially DOPA.
[0056] However, it is further preferred that:
[0057] G 1 Represents Ala;
[0058] G 2 represents Ser;
[0059] T stands for Tyr;
[0060] G 3 represents 1 to 4 (e.g., 1 to 3) amino acid residues, each of which is independently selected from Tyr, 3Hyp, 4Hyp and Thr, for example, the amino acid chain consists of -V 1 -Thr-Tyr-V 2 - indicates that V 1 Bonded to Hyp and V 2 Bonded to Lys, and V 1 and V 2 Independently, none, one or two Hyp groups are present.
[0061] In this regard, Sequence-V 1 -Thr-Tyr-V 2 It can be represented by the following partial sequence in increasing order of precedence:
[0062] -Hyp-Thr-Tyr-
[0063] -Hyp-Thr-Tyr-Hyp- or
[0064] -Thr-Tyr-Hyp-.
[0065] Thus, preferred peptide components include those having the following amino acid sequence:
[0066] Ala-Lys-Pro-G 2 -T-Hyp-Hyp-Thr-G 4 -Lys (SEQ ID No: 9),
[0067] Among them G 2 , T and Hyp are defined above, and G 4 is selected from Tyr, pTyr, 3Hyp, 4Hyp, Thr, pThr and DOPA, wherein G 2 More preferably, Ser is selected, T is more preferably selected as Tyr, and G is 4 Tyr or DOPA is more preferred.
[0068] Preferred peptide components also include those having the following amino acid sequence:
[0069] Ala-Lys-Pro-G 2 -T-Hyp-Thr-G 4 -Hyp-Lys (SEQ ID No: 10),
[0070] Among them G 2 , T, Hyp and G 4 is defined above, where G 4 More preferred are DOPA or especially Tyr.
[0071] Preferred peptide components include those having the following amino acid sequence:
[0072] Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Lys (SEQ ID No: 4);
[0073] Ala-Lys-Pro-pSer-Tyr-Hyp-Hyp-Thr-DOPA-Lys (SEQ ID No: 11);
[0074] Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Lys (SEQ ID No: 12);
[0075] Ala-Lys-Pro-pSer-Tyr-Hyp-Hyp-Thr-Tyr-Lys (SEQ ID No: 13);
[0076] Lys-Pro-Ser-Tyr-Hyp-DOPA-Lys (SEQ ID No: 14); and
[0077] Lys-Pro-Ser-pTyr-Hyp-DOPA-Lys (SEQ ID No: 15).
[0078] In the above amino acid sequence listing, Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Lys (SEQ ID No: 12) is most preferred.
[0079] Further preferred peptide components include those having the following amino acid sequence:
[0080] Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-pThr-DOPA-Lys (SEQ ID No: 16) and
[0081] Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-pThr-Tyr-Lys (SEQ ID No: 17).
[0082] Further preferred peptide components include those having the following amino acid sequence:
[0083] Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 18);
[0084] Ala-Lys-Pro-pSer-Tyr-Hyp-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 19);
[0085] Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 20);
[0086] Ala-Lys-Pro-pSer-Tyr-Hyp-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 21);
[0087] Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 22);
[0088] Ala-Lys-Pro-pSer-Tyr-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 23);
[0089] Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 24);
[0090] Ala-Lys-Pro-pSer-Tyr-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 25);
[0091] Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-pThr-DOPA-Hyp-Lys (SEQ ID No: 26); and
[0092] Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-pThr-Tyr-Hyp-Lys (SEQ ID No: 27).
[0093] In the above amino acid sequence listing, Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 24) is most preferred.
[0094] Further preferred peptide components include those having the following amino acid sequence:
[0095] Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA (SEQ ID No: 28);
[0096] Ala-Lys-Pro-pSer-Tyr-Hyp-Hyp-Thr-DOPA (SEQ ID No: 29);
[0097] Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr (SEQ ID No: 30);
[0098] Ala-Lys-Pro-pSer-Tyr-Hyp-Hyp-Thr-Tyr (SEQ ID No: 31);
[0099] Lys-Pro-Ser-Tyr-Hyp-DOPA (SEQ ID No: 32);
[0100] Lys-Pro-Ser-pTyr-Hyp-DOPA (SEQ ID No: 33);
[0101] Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-pThr-DOPA (SEQ ID No: 34);
[0102] Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-pThr-Tyr (SEQ ID No:35);
[0103] Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Hyp (SEQ ID No:36);
[0104] Ala-Lys-Pro-pSer-Tyr-Hyp-Hyp-Thr-DOPA-Hyp (SEQ ID No:37);
[0105] Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Hyp (SEQ ID No:38);
[0106] Ala-Lys-Pro-pSer-Tyr-Hyp-Hyp-Thr-Tyr-Hyp (SEQ ID No:39);
[0107] Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-DOPA-Hyp (SEQ ID No:40);
[0108] Ala-Lys-Pro-pSer-Tyr-Hyp-Thr-DOPA-Hyp (SEQ ID No:41);
[0109] Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-Hyp (SEQ ID No:42);
[0110] Ala-Lys-Pro-pSer-Tyr-Hyp-Thr-Tyr-Hyp (SEQ ID No:43);
[0111] Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-pThr-DOPA-Hyp (SEQ ID No:44);
[0112] Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-pThr-Tyr-Hyp (SEQ ID No:45);
[0113] Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp (SEQ ID No:46); and
[0114] Ala-Lys-Pro-Ser-Tyr-Hyp (SEQ ID No:47).
[0115] The skilled artisan will appreciate that metabolites of the compounds of the invention that may be formed following administration are included within the scope of the invention.
[0116] Specifically, the compounds of the present invention comprising a peptide component having an amino acid sequence of SEQ ID No: 28 to SEQ ID No: 47 can be formed as metabolites of the corresponding compounds of the present invention comprising the relevant amino acids at the C-terminus, and the metabolites can be cleaved from other compounds of the present invention after administration.
[0117] For example, a compound of the present invention comprising a peptide component having the amino acid sequence of SEQ ID No: 30, SEQ ID No: 46, and SEQ ID No: 47 can be formed as a metabolite of a compound of the present invention comprising a peptide component having the amino acid sequence of SEQ ID No: 12. Similarly, a compound of the present invention comprising a peptide component having the amino acid sequence of SEQ ID No: 42 and SEQ ID No: 47 can be formed as a metabolite of a compound of the present invention comprising a peptide component having the amino acid sequence of SEQ ID No: 24.
[0118] However, the compounds of the invention comprising a peptide component having an amino acid sequence of SEQ ID No: 28 to SEQ ID No: 47 are themselves also compounds of the invention and can be manufactured, formulated and administered to patients in exactly the same manner as other compounds of the invention described herein and / or exemplified below.
[0119] For the avoidance of doubt, as used herein, Pro represents proline, Ala represents alanine, Ser represents serine, and pSer represents phosphoserine, Tyr represents tyrosine, pTyr represents phosphotyrosine, Hyp represents hydroxyproline (3Hyp represents 3-hydroxyproline, and 4Hyp represents 4-hydroxyproline). Thr represents threonine, pThr represents phosphothreonine (or phosphothreonine). And Lys, Ala and DOPA are as defined above. The phosphonated derivatives of amino acids containing free hydroxyl groups (e.g., Ser, Tyr and Thr) contain -OP(=O)(OH)2 groups instead of -OH.
[0120] One or more compounds of Formula I may be linked to the above peptide components via one or more, for example, Ala or Lys moieties (including via an N-terminal Ala or Lys moiety and / or a C-terminal Lys moiety).
[0121] In the compounds of the present invention, three compounds of formula I, preferably two compounds of formula I, and more preferably one compound of formula I may be covalently bonded to the above-mentioned peptide component.
[0122] Advantageously, the peptide component of the compounds of the invention comprises at least one amino acid residue containing at least one free -NH2 group. Specific amino acid residues containing at least one free -NH2 group include Asn, Gln, preferably Arg, and most preferably Lys. For example, when the peptide component is G 1 -Lys-Pro-G 2 -T-Hyp-G 3 -Lys (SEQ ID No: 7), at least one of the Lys residues has a free -NH2 group (ie, at least one of the Lys residues is not covalently bonded to a compound group of Formula I).
[0123] In the case of compounds of the invention in which two or more (e.g., three, preferably two) compounds of Formula I are covalently bonded to a peptide component, it is preferred that the peptide component comprises at least one amino acid residue comprising at least one free -NH2 group. For example, the peptide component comprises at least one Lys residue that is not covalently bonded to a compound of Formula I.
[0124] Without wishing to be bound by theory, it is believed that the presence of free -NH2 groups in the peptide component (e.g., when one or more Lys residues that may be present are not covalently bonded to the compound of Formula I) is beneficial to the solubility (e.g., aqueous solubility) of the compounds of the invention.
[0125] The compounds of Formula I contain double bonds and may therefore exist as E (trans (entgegen)) and Z (cis (zusammen)) geometric isomers about said double bonds. All such isomers and mixtures thereof are included within the scope of the present invention. For the avoidance of doubt, the compounds of Formula I Indicates that the 7-chloroquinoline ring can be cis (as a Z geometric isomer) or trans (as an E geometric isomer) positioned across the double bond to the central 1,3-disubstituted benzene ring. Preferably, the 7-chloroquinoline ring is trans positioned across the double bond to the central 1,3-disubstituted benzene ring, that is, the E geometric isomer.
[0126] Specific compounds of formula I that may be mentioned include those wherein R 1 Those selected from -C(CH3)2OH, -COCH3 and -C(CH3)=CH2.
[0127] Preferred compounds of formula I include those wherein R 1 Those wherein -C(CH3)2OH and / or n is 0 (e.g., montelukast).
[0128] For the avoidance of doubt, montelukast has the following chemical structure:
[0129]
[0130] Other compounds of Formula I include those wherein R 1 Those wherein -C(CH3)=CH2 and / or n is 0 (eg, montelukast styrene).
[0131] For the avoidance of doubt, montelukast styrene has the following chemical structure:
[0132]
[0133] Other compounds of formula I that may be mentioned include those wherein R 1 Those wherein -C(CH3)2H and / or n is 0 (e.g., hydrogenated montelukast styrene).
[0134] For the avoidance of doubt, montelukast styrene hydrogenated has the following chemical structure:
[0135]
[0136] The compounds of the invention, whether in salt form or otherwise, include regioisomers within the amino acids (e.g., Hyp and Tyr moieties) of the peptide component, as well as mixtures of such regioisomers. For example, the definition of Tyr includes not only tyrosine (4-hydroxyphenylalanine), but also 2- and 3-hydroxyphenylalanine, and the definition of Hyp includes 4-hydroxyproline (4Hyp), 3-hydroxyproline (3Hyp), and 5-hydroxyproline (5Hyp). More preferably, the Hyp residue is 4-hydroxyproline.
[0137] In addition, in addition to the standard central carbon atom of the amino acids in the peptide component of the compounds of the invention (usually but not exclusively in the L-configuration), some of the amino acids in the sequence also contain additional chiral carbon atoms. All such stereoisomers and mixtures thereof (including racemic mixtures) are included within the scope of the present invention. In this regard, the definition of Hyp includes trans-4-hydroxy-L-proline, cis-4-hydroxy-L-proline, trans-3-hydroxy-L-proline, cis-3-hydroxy-L-proline, trans-5-hydroxy-L-proline and cis-5-hydroxy-L-proline, but we prefer that the Hyp used in the compounds of the present invention is 4-hydroxy-L-proline. Similarly, the individual enantiomers of the compounds of formula I that may form part of the compounds of the present invention are included within the scope of the present invention.
[0138] The compounds of the present invention may be in the form of a salt. Salts that may be mentioned include pharmaceutically acceptable and / or cosmetically acceptable salts, such as pharmaceutically and / or cosmetically acceptable acid addition salts and base addition salts. Such salts may be formed in a conventional manner, for example, by the following means: the compounds of the present invention are reacted with one or more equivalents of appropriate acid or base, optionally in a solvent or in a medium in which the salt is insoluble, followed by removal of the solvent or the medium using standard techniques (e.g., in a vacuum, by freeze drying or by filtering). Salts may also be prepared by, for example, exchanging the counter ions of the active ingredient in the form of a salt with another counter ion using a suitable ion exchange resin.
[0139] Preferred salts include, for example, acetate, hydrochloride, bisulfate, maleate, methanesulfonate, toluenesulfonate, alkaline earth metal salts (such as calcium and magnesium), or alkali metal salts (such as sodium and potassium salts).Most preferably, the compounds of the present invention may be in the form of acetate salts.
[0140] The compounds of the present invention can be prepared by conventional techniques. For example, the compounds of the present invention can be manufactured by coupling one or more compounds of formula I with peptide components, such as described below. The compounds of the present invention (and their peptide components) can be synthesized by available starting materials using appropriate reagents and reaction conditions. In this regard, technicians can refer to "Comprehensive Organic Synthesis", BMTrost and I.Fleming, Pergamon Press, 1991. Other references that can be used include "Heterocyclic Chemistry", JA Joule, K. Mills and GF Smith, 3rd edition, published by Chapman & Hall, "Comprehensive Heterocyclic Chemistry II", AR Katritzky, CW Rees and EF V Scriven, Pergamon Press, 1996 and "Science of Synthesis", Vol. 9-17 (Hetarenes and Related Ring Systems), Georg Thieme Verlag, 2006.
[0141] If desired, the peptide component of the compositions of the invention may be made by standard peptide synthesis techniques using standard amino acid coupling techniques and standard coupling reagents and solvents, for example as described below.
[0142] Technicians should understand that, can be used for preparing the method for the compounds of the present invention described above after or during, by methods well known to those skilled in the art, the substituents as defined herein and the substituents thereon are modified once or many times.The example of such method includes substitution, reduction, oxidation, dehydrogenation, alkylation, dealkylation, acylation, hydrolysis, esterification, etherification, halogenation and nitration.At any time during the reaction sequence, the precursor group can be changed to different such groups, or the group defined in the compounds of the present invention.Technicians can also refer to " Comprehensive Organic Functional Group Transformations ", ARKatritzky, O.Meth-Cohn and CWRees, Pergamon Press, 1995 and / or " Comprehensive Organic Transformations ", RCLarock, Wiley-VCH, 1999.
[0143] The compounds of the present invention can be isolated from their reaction mixtures and, if desired, purified using conventional techniques known to those skilled in the art. Thus, the methods for preparing the compounds of the present invention as described herein may include separating and optionally purifying the compounds of the present invention (as a final step).
[0144] Those skilled in the art will appreciate that in the methods described above and below, it may be necessary to protect the functional groups of the intermediate compounds by protecting groups. The protection and deprotection of the functional groups can be carried out before or after the reactions in the above schemes.
[0145] The protecting group can be applied and removed according to the technology well known to those skilled in the art and as described below. For example, the protected compound / intermediate as described herein can be chemically converted into an unprotected compound using standard deprotection techniques. The involved chemical types will determine the needs and type of the protecting group, and the order of realizing synthesis. The use of protecting groups is fully described in " Protective Groups in Organic Synthesis ", the 3rd edition, TW Greene & P.GMWutz, Wiley-Interscience (1999), and its content is incorporated herein by reference.
[0146] The compounds of the invention are useful because they have pharmacological activity. Therefore, the compounds of the invention can be used as human and animal medicines. Therefore, although they can also be used as cosmetics and / or as part of a medical device, they are indicated as drugs (and / or in veterinary science).
[0147] Although the compounds of the invention may themselves have pharmacological activity, certain pharmaceutically acceptable (e.g., "protected") derivatives of the compounds of the invention may exist or may be prepared which may not have such activity, but which may be administered and then metabolized or chemically converted to form the compounds of the invention. Such compounds (which may have some pharmacological activity, provided that such activity is significantly less than the activity of the active compound to which it is metabolized / converted) may therefore be described as "prodrugs" of the compounds of the invention.
[0148] As used herein, reference to a prodrug will include compounds that form a compound of the invention in an experimentally detectable amount within a predetermined time after administration. All prodrugs of the compounds of the invention are included within the scope of the invention.
[0149] The compounds of the invention are particularly useful in the treatment of inflammation.
[0150] "Treatment of inflammation" includes treatment of inflammation (regardless of cause) in any organ of the body, including soft tissues, joints, nerves, the vascular system, internal organs, especially mucosal surfaces, and especially the skin, and also includes all such inflammatory disorders or conditions, and / or disorders or conditions characterized by inflammation (e.g., as a symptom).
[0151] Inflammatory disorders can be (and typically are) characterized by activation of immune defense mechanisms that produce effects that do more harm than good to the host. Such disorders are often associated with varying degrees of tissue redness or hyperemia, swelling, edema, hyperthermia, pain (including aching), fluid exudation, itching (pruritus), cell death and tissue destruction, cell proliferation, and / or loss of function.
[0152] Inflammations that may be mentioned include arteritis, diabetes, metabolic syndrome, rosacea, asthma and allergies, ankylosing spondylitis, chronic obstructive pulmonary disease, gouty arthritis, inflammatory bowel diseases (such as Crohn's disease and ulcerative colitis), multiple sclerosis, osteoarthritis, pancreatitis, prostatitis, psoriatic arthritis, rheumatoid arthritis, tendinitis, bursitis, Sjögren's syndrome, systemic lupus erythematosus, uveitis, urticaria, vasculitis, mastocytosis, diabetic vascular complications, migraine, atherosclerosis and related cardiovascular disorders. Disease states characterized by inflammation that may be mentioned are chronic obstructive pulmonary disease (COPD). Other disease states characterized by inflammation that may be mentioned are inflammatory bowel diseases, including Crohn's disease and especially ulcerative colitis.
[0153] Inflammatory disorders that may be mentioned more particularly include inflammation of the skin or mucous membranes (including oral mucosa, nasal mucosa, ocular mucosa, vaginal mucosa, cervical mucosa and / or anorectal mucosa, more particularly oral mucosa or nasal mucosa), such as inflammation caused by infection (such as viral infection and / or bacterial infection), or allergic / atopic disorders (such as rhinitis (e.g., allergic rhinitis), pharyngitis, periodontitis, gingivitis, dry eyes, conjunctivitis (e.g., allergic conjunctivitis), dermatitis, urticaria (hives) and food allergies); and other inflammatory disorders, such as herpes, drug eruptions, polymorphous light eruptions, sunburn, early manifestations of skin cancer (erythematous skin lesions), pathological alopecia (including after skin transplants), chemotherapy rash, psoriasis, erythema multiforme, folliculitis, eczema and otitis externa. A disease state that may be mentioned is polymorphous light eruption.
[0154] More particularly, the compounds can be used to treat certain conditions characterized by and / or associated with inflammation. Such conditions can include wounds (including abrasions (scratches), incisions (including surgical incisions), tears, punctures, avulsions, bruises and scars) and burns (including inflammation caused by surgical procedures (such as skin grafts) after burns) and other conditions, such as hemorrhoids. Wounds can be acute or chronic, and / or can be caused by one or more inflammatory disorders as defined herein.
[0155] Wounds of the skin or mucous membranes may result from internal or external physical injury to the membrane surface, or may be caused by (ie, be a symptom of) an underlying physiological disorder.
[0156] Physical (e.g., "open") wounds may be caused by sharp objects (cuts, incisions, punctures) or blunt objects / mechanical forces (lacerations, abrasions, avulsions), physical blows (bruises), heat or chemicals (burns and blisters), ultraviolet light (sunburn), cold (chilblains or frostbite). Wounds may be superficial (damage to the epidermis and / or dermis only), or may be full thickness wounds (damage below the epidermis and / or dermis). In severe cases, subcutaneous and / or submucosal tissues such as muscle, bone, joints, and even internal organs may be damaged.
[0157] The compounds of the present invention can be used to relieve pain (including dull pain) associated with inflammation and / or wounds. Specifically, the compounds of the present invention can be used to relieve procedural pain and / or non-procedural pain. It will be appreciated by the technician that the term "procedural pain" (i.e., surgical pain) refers to acute pain associated with medical research and treatment for health care purposes. The term "non-procedural" refers to general pain associated with inflammation and / or wounds (e.g., pain associated with dental ulcers, burns, and / or scars), and is not the result of a specific medical intervention.
[0158] The compounds of the present invention are not only useful for treating inflammation, pain (including dull pain) and / or pruritus (itch) associated with the wound itself and the healing process, they are also useful for preventing the leakage of body fluids from the wound, the risk of infection, and also the prevention of physiological responses caused by inflammation and / or the wound healing process (such as scarring and pigmentation).
[0159] Scarring is the result of inflammation and / or wound healing, and is a general term for the formation of fibrous tissue as a result of such inflammation / healing.
[0160] The compounds of the present invention may also be used to inhibit the production of melanin pigmentation, which may or may not be caused by inflammation and / or wound healing. The compounds of the present invention may also be used to inhibit disorders associated with melanin pigmentation, such as chloasma, freckles, melanosis, cheek rashes and other pigmentation disorders, skin cancers associated with melanoma, and pigmentation disorders or skin diseases caused by exposure to sunlight (like acne).
[0161] Wounds may also be caused as a result of (e.g., inflammatory) diseases or disorders. Such wounds may include blisters and / or ulcers of the skin and mucous membranes. These are common conditions that are usually long-lasting and difficult to treat. Skin tissue may often be damaged, removed, liquefied, infected and / or necrotic. Ulcers may cause secondary consequences to health (especially if they become infected), are difficult to cure and expensive to treat. They may also cause significant psychological stress and economic losses to patients, thereby affecting both overall well-being and quality of life.
[0162] In alternative embodiments, inflammatory skin conditions or diseases in which the compounds of the invention are found to be particularly useful include psoriasis, acne, eczema and dermatitis, especially allergic dermatitis / atopic dermatitis, and in the treatment of mucosal inflammation such as characterized by, for example, rhinitis (especially allergic rhinitis) hemorrhoids, chronic obstructive pulmonary disease and ulcerative colitis.
[0163] Psoriasis is a chronic inflammatory skin disease with a tendency to relapse (some patients remain incurable throughout their lifetime). The clinical manifestations of psoriasis mainly include erythema and scaling. It can occur throughout the body, but is more often observed on the scalp and limbs.
[0164] Acne is a follicular (pilosebaceous unit) chronic inflammatory skin disease, the occurrence of which is closely related to major factors such as excessive sebum secretion, obstruction of the pilosebaceous ducts (including closed comedones and open comedones), bacterial infection and inflammatory response, which tends to occur in youth and is characterized by polymorphic skin lesions on the face. Therefore, the term acne includes common acne and rosacea (i.e., rosacea).
[0165] Eczema is an inflammatory reaction of the skin with intense itching caused by a variety of internal and external factors. It has three stages: acute, subacute and chronic. In the acute stage, there is a tendency for exudate to be produced, while the chronic stage includes infiltration and hypertrophy. Skin lesions are usually itchy and tend to recur.
[0166] Dermatitis is a common skin disease characterized by roughness, redness, itching, eczema, and dryness. If not treated quickly, small patches, stubborn ulcers, and pigmented macules caused by dermatitis may progress to basal cell carcinoma, squamous cell carcinoma, and malignant melanoma. Dermatitis may be caused by a variety of internal and external infectious or non-infectious factors, including substances (contact dermatitis) or allergies (allergic / atopic dermatitis). Also included are seborrheic dermatitis (seborrheic eczema) and all forms of steroid-dependent dermatitis (including photosensitivity seborrheic dermatitis, perioral dermatitis, rosacea-like dermatitis, steroid-rosacea, steroid-induced rosacea, iatrogenic rosacea, steroid-like rosacea, topical corticosteroid-induced rosacea-like dermatitis, and more particularly facial corticosteroid addiction dermatitis (FCAD) or facial corticosteroid-dependent dermatitis (FCDD), such as characterized by flushing, erythema, telangiectasia, atrophy, papules and / or pustules in the facial area after long-term treatment with (including uncontrolled use, abuse or misuse) topical corticosteroids; see, e.g., Xiao et al., J. Dermatol., 42, 697 (2015) and Lu et al., Clin. Exp. Dermatol., 35, 618 (2009)).
[0167] Rhinitis is an irritation and inflammation of the mucous membranes inside the nose. Common symptoms of rhinitis include nasal congestion, runny nose, sneezing, and postnasal drip. The most common type of rhinitis is allergic rhinitis caused by allergens such as pollen, dust, mold, or flakes of skin of certain animals. It has been unexpectedly discovered that patients with allergic rhinitis treated with the compounds of the invention experience relief of ocular itching even when the compounds of the invention are administered nasally (i.e., to the nasal mucosa).
[0168] Hemorrhoids are swellings caused by inflammation of the hemorrhoidal blood vessels present in or around the rectum and anus. Symptoms include bleeding after stool is passed (i.e., hurting), hemorrhoidal prolapse, mucus discharge, and itching, pain, redness, and swelling in the anal area. Hemorrhoids are believed to be the result of increased abdominal pressure, for example, as a result of constipation or diarrhea.
[0169] Chronic obstructive pulmonary disease (COPD) is the name of a group of lung conditions that cause breathing difficulties, including emphysema (damage to the alveoli) and chronic bronchitis (long-term inflammation of the airways). COPD occurs when the lungs become inflamed, damaged, and narrowed. Damage to the lungs is usually irreversible and causes damage to the air flow in and out of the lungs. Symptoms of COPD include shortness of breath, productive cough, frequent chest infections, and persistent wheezing. The most common cause of the disease is smoking, although other risk factors include high levels of air pollution and occupational exposure to dust, chemicals, and fumes.
[0170] The compounds of the present invention may have a positive effect in alleviating erythema, redness and swelling, edema, blisters and bullous pemphigoid caused by various conditions including those mentioned generally and specifically herein, and may inhibit the exudation of subcutaneous tissue fluid, and inhibit the itching and pain caused by such inflammatory conditions.
[0171] Other inflammatory conditions that may be mentioned include:
[0172] (a) Mucosal inflammations, such as oral mucositis, aphthous ulcers, otitis media, laryngitis, tracheitis, esophagitis, gastritis, enteritis and enterocolitis (including bacillary dysentery, chronic amoebic dysentery, schistosomiasis, nonspecific ulcerative colitis and Crohn's disease), cervicitis and endocervicitis, endometritis, inflammation caused by inhalation injury, etc., and mucosal inflammations associated with cancer and infections (e.g., viral infections such as the common cold or influenza), which affect mucosal surfaces, such as those in the oral cavity, nasopharynx, ear, throat, trachea, gastrointestinal tract, cervix, etc.
[0173] (b) Orthopedic inflammation associated with, for example, fractures, suppurative infections of bones and joints, inflammation caused by rheumatic bone diseases, as well as suppurative osteomyelitis (acute, chronic, localized, sclerotic, post-traumatic), suppurative arthritis; bone tumors (osteomas, osteoid osteomas, enchondromas), bone cysts, osteoclastomas, primary osteosarcomas (osteosarcomas, chondrosarcomas, fibrosarcomas of bone, Ewing's sarcoma, non-Hodgkin's lymphomas, myeloma, chordomas), metastatic bone tumors, tumor-like lesions of the bone (bone cysts, aneurysmal bone cysts, eosinophilic granulomas, fibrous dysplasia); and rheumatoid arthritis.
[0174] (c) Neuroinflammation, such as peripheral polyneuritis, facial neuritis, peripheral neuritis, subcutaneous neuritis, ulnar neuritis, intercostal neuritis, etc.
[0175] (d) Inflammation of subcutaneous and submucosal soft tissues, such as myositis, ligamentitis, tendinitis, panniculitis, cystitis, lymphadenitis, buboes, tonsillitis, synovitis, fasciitis, and inflammation of muscles, ligaments, fascia, 、 tendon、 Soft tissue inflammation caused by injury, contusion or tear of the synovium, fat, joint capsule and lymphatic tissue.
[0176] (e) Vascular inflammation, such as allergic leukocytoclastic vasculitis, allergic cutaneous vasculitis, polyarteritis nodosa, thrombotic vasculitis, granulomatous vasculitis, lymphocytic vasculitis, vasculitis with abnormal blood composition, and rheumatic vasculitis, and vascular inflammation associated with vascular cancer caused by allergic leukocytoclastic vasculitis, polyarteritis nodosa, thrombotic vasculitis, granulomatous vasculitis, lymphocytic vasculitis, vasculitis with abnormal blood composition, and rheumatic vasculitis.
[0177] (f) Inflammation of internal organs such as the heart, stomach, intestines, lungs, liver, spleen, kidneys, pancreas, bladder, ovaries and prostate, including but not limited to pericarditis, myocarditis, endocarditis, pneumonia, hepatitis, splenitis, nephritis, pancreatitis, cystitis, oophoritis, prostatitis and treatment of gastric ulcers.
[0178] (g) Inflammation of the eye and surrounding areas, such as conjunctivitis, keratitis (e.g., acute epithelial keratitis, coin-shaped keratitis, interstitial keratitis, disciform keratitis, neurotrophic keratitis, mucomacular keratitis, herpes simplex keratitis, herpes zoster keratitis, bacterial keratitis, fungal keratitis, Acanthamoeba keratitis, onchocercal keratitis, superficial punctate keratitis, ulcerative keratitis, exposure keratitis, photokeratitis, and acute red eye caused by contact lenses), optic neuritis, etc.
[0179] (h) Inflammation of the gums and oral cavity, such as periodontitis, gingivitis, tooth ulcers, etc.
[0180] (i) Inflammation associated with rheumatic diseases, such as rheumatic vasculitis, rheumatoid arthritis, rheumatic bone disease, ankylosing spondylitis, bursitis, Crohn's disease, gout, infectious arthritis, juvenile idiopathic arthritis, osteoarthritis, osteoporosis, polymyalgia rheumatica, polymyositis, psoriatic arthritis, scleroderma, Sjögren's syndrome, spondyloarthropathies, systemic lupus erythematosus, tendinitis, etc.
[0181] The compounds of the present invention can also be used to treat certain specific diseases of the respiratory system, such as cystic fibrosis, common interstitial pneumonia, hypersensitivity pneumonitis, asbestosis, emphysema, cor pulmonale, pulmonary embolism, etc. Among the specific disease states that can be mentioned is idiopathic pulmonary fibrosis.
[0182] Idiopathic pulmonary fibrosis is a diffuse and fatal interstitial lung disease, whose pathological features include alveolar epithelial damage, massive proliferation of lung fibroblasts, and excessive deposition of extracellular matrix, which ultimately lead to irreversible lung tissue damage. In the later stages of the disease, subjects with idiopathic pulmonary fibrosis experience respiratory failure and death. It has been found that the compounds of the present invention can be used to treat idiopathic pulmonary fibrosis and / or alleviate symptoms associated with the disease.
[0183] The compounds of the invention are particularly useful for treating the following pulmonary and / or fibrotic disorders (whether or not mentioned elsewhere herein): pulmonary fibrosis, renal fibrosis, hepatic fibrosis, silicosis, acute bronchitis, chronic bronchitis, tracheobronchitis, bronchial asthma, status asthmatics, bronchiectasis, upper respiratory tract infections (including the common cold and influenza), allergic airway inflammation, bacterial pneumonia, viral pneumonia, mycoplasma pneumonia, rickettsia, radiation pneumonia, pneumococcal (including staphylococcal, streptococcal and gram-negative bacilli) pneumonia, pulmonary candidiasis (including aspergillosis, mucormycosis, histoplasmosis, actinomycosis and nocardiosis), pulmonary fungal diseases, cryptococcosis, lung abscess, hypersensitivity pneumonitis (Leoffer's syndrome), extrinsic allergic alveolitis, pulmonary eosinophilia (pulmonary eosinophilia), obstructive emphysema, pulmonary edema, pulmonary tuberculosis, respiratory alkalosis (acidosis), acute lung injury, interstitial lung disease, empyema, pulmonary fibrosis and cor pulmonale.
[0184] Specific mucosal disorders and diseases in which the compounds of the invention are found useful include, for example, anorectal diseases such as diarrhea, hemorrhoids, abscesses, fistulas, fissures, anal pruritus, anal sinusitis, warts and rectal prolapse; inflammatory bowel disease, including Crohn's disease and, in particular, ulcerative colitis; gynecological diseases such as cervicitis, vaginitis, pelvic pain and disorders; and dental diseases such as periodontitis.
[0185] The compounds of the present invention may further have an antioxidant effect by increasing the production of SOD (superoxide dismutase) and reducing lipid oxidation. The compounds of the present invention may therefore be considered to have antioxidant properties.
[0186] The compounds of the invention may also have antipyretic properties, which allow for the treatment of fever and / or alleviation of its symptoms; for example, by lowering the subject's body temperature, which results in a reduction in fever. Therefore, the compounds of the invention and formulations containing them may be considered antipyretics.
[0187] According to a further aspect of the invention, there is provided a method of treating inflammation, inflammatory disorders, and / or disorders / conditions characterized by inflammation (eg, as a symptom), comprising administering to a patient in need of such treatment a compound of the invention.
[0188] For the avoidance of doubt, in the context of the present invention, the terms "treatment", "therapy" and "method of treatment" include therapeutic or palliative treatment of a patient in need thereof as well as prophylactic treatment and / or diagnosis of patients susceptible to inflammation and / or inflammatory disorders.
[0189] The compounds of the invention may further have antiviral properties, such as, as opposed to the treatment of any symptoms of any viral infection or disease (such as pain and / or inflammation), the antiviral properties allow the treatment of viral infections in essence, i.e., the treatment of viral infections or viral diseases by interfering with viral replication in the host. Such antiviral properties may also allow the prevention of the onset of such infections or diseases, the protection of host cells from (e.g., further) viral infection, the prevention or cessation of the spread of viral infections or diseases (within a single host, or from one host to a new host), or the prevention of reactivation of viruses after latency in a host.
[0190] According to another aspect of the present invention, there is provided a method of treating viral infection, the method comprising administering a compound of the present invention or a salt thereof to a patient in need of such treatment.
[0191] Viral infections that may be mentioned include those caused by viruses of the following families: Adenoviridae (e.g. adenovirus), Papillomaviridae (e.g. human papillomavirus), Polyomaviridae (e.g. BK virus; JC virus), Herpesviridae (e.g. herpes simplex type 1; herpes simplex type 2; varicella zoster virus; Epstein-Barr virus; human cytomegalovirus; human herpesvirus type 8), Poxviridae (e.g. smallpox), Hepadnaviridae (e.g. hepatitis B virus), Parvoviridae (e.g. parvovirus B19), Astroviridae (e.g. human astrovirus), Caliciviridae (e.g. norovirus; Norwalk virus). virus), Picornaviridae (e.g., coxsackievirus, hepatitis A virus; poliovirus; rhinovirus), Coronaviridae (e.g., severe acute respiratory syndrome virus), Flaviviridae (e.g., hepatitis C virus; yellow fever virus; dengue virus; West Nile virus; tick-borne encephalitis virus), Retroviridae (e.g., human immunodeficiency virus; HIV), Togaviridae (e.g., rubella virus), Arenaviridae (e.g., Lassa virus), Bunyaviridae (e.g., hantavirus; Crimean-Congo hemorrhagic fever virus; Hantaan virus), Filoviridae (e.g., Ebola virus; Marburg virus; Ravn virus), virus), Orthomyxoviridae (e.g., influenza virus, including influenza A virus (e.g., H1N1 and H3N2 virus), influenza B virus or influenza C virus), Paramyxoviridae (e.g., measles virus; mumps virus; parainfluenza virus, respiratory syncytial virus), Rhabdoviridae (e.g., rabies virus), Hepaciviridae (e.g., hepatitis E virus), Reoviridae (e.g., rotavirus; orbivirus; Colorado tick fever virus (coltivirus); Banna virus), and viruses of unspecified families, such as hepatitis D virus.
[0192] Viruses that may be mentioned more particularly include herpes simplex virus type 1 and type 2, human papillomavirus, influenza virus and parainfluenza virus.
[0193] The compounds of the present invention may further have antibacterial and / or bacteriostatic properties, such as, contrary to the treatment of any symptoms of any bacterial infection or disease (such as pain and / or inflammation), which properties may allow the bacterial infection to be treated in essence, i.e., by interfering with the growth or proliferation of bacteria in the host to treat the bacterial infection or bacterial disease. Therefore, the compounds of the present invention may be considered as bactericides and / or preferably bacteriostatics.
[0194] Such antibacterial properties may also allow for prevention of the onset of such infection or disease, protection of host cells from (e.g., further) bacterial infection, prevention or cessation of the spread of bacterial infection or disease (within a single host, or from one host to a new host), or prevention of reactivation of bacteria after latency in a host.
[0195] According to a further aspect of the present invention, there is provided a method of treating a bacterial infection, the method comprising administering a compound of the present invention or a salt thereof to a patient in need of such treatment.
[0196] As disclosed herein, the compounds of the invention may further have anti-cancer properties, such as, as opposed to treatment of any symptoms of cancer (such as pain and / or inflammation), which may allow for the treatment of cancer in essence, i.e., as opposed to treating cancer by interfering with it. Such anti-cancer properties may also include preventing the onset of such diseases, for example, by treating inflammation and thereby preventing such onset.
[0197] According to another aspect of the present invention, there is provided a method for treating cancer, which comprises administering a compound of the present invention or a salt thereof to a patient in need of such treatment.
[0198] Specific cancers that may be mentioned include oral cancer, nasopharyngeal cancer, middle ear cancer, conjunctival cancer, throat cancer, tracheal cancer, esophageal cancer, stomach cancer, intestinal cancer, cervical cancer, endometrial cancer, skin cancer, etc. caused by oral mucositis, rhinitis, otitis media, conjunctivitis, pharyngitis, laryngitis, tracheitis, esophageal cancer, gastric cancer, enterocolitis, cervicitis, endometritis, erythematous skin lesions, etc. A specific skin cancer that may be mentioned is basal cell carcinoma.
[0199] "Patient" includes reptilian patients, avian patients and preferably mammalian (especially human) patients.
[0200] According to the present invention, the compounds of the present invention are preferably administered topically or systemically, for example orally, intravenously or intraarterially (including via intravascular and other perivascular devices / dosage forms (e.g., stents)), intramuscularly, cutaneously, subcutaneously, transmucosally (e.g., sublingually or buccally), rectally, intravaginally, transdermally, nasally, pulmonary (e.g., tracheally or transbronchially), preferably topically, or by any other parenteral route in the form of a pharmaceutical formulation comprising one or more compounds in one or more pharmaceutically acceptable dosage forms.
[0201] Administration by inhalation (eg, nasal) is particularly useful when the condition to be treated is rhinitis or inflammation caused by a viral infection of the airways (eg, upper respiratory tract infections such as the common cold and flu).
[0202] Pulmonary administration is particularly useful when the condition to be treated is COPD or IPF.Topical administration forms may be enhanced by producing a spray containing the active ingredient, for example by using a powder aerosol or by means of an aqueous mist using an appropriate atomization technique or device such as a nebulizer.
[0203] Anorectal administration is particularly useful when the condition to be treated is hemorrhoids or ulcerative colitis, using appropriate delivery means, such as foam solutions to be injected or suppositories.
[0204] Administration to the lower gastrointestinal tract can also be achieved by parenteral and particularly by oral delivery, with the aid of standard delayed or extended release coating techniques known to those skilled in the art. Specifically, different parts of the upper or lower intestine can be targeted. For example, colonic administration can also be achieved by a drug delivery device that is initially administered orally or parenterally and is targeted to the colon.
[0205] Preferred modes of delivery of the compounds of the invention include topical application to the site of inflammation (e.g., mucosa (including oral and / or nasal mucosa, lungs, anorectal area and / or colon), or more preferably skin) in an appropriate (e.g., pharmaceutically acceptable and topically acceptable) vehicle and / or commercially available formulation suitable for application to the skin and / or appropriate mucosal surfaces, but may also include oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular, intraperitoneal or pulmonary delivery.
[0206] The compounds of the invention will generally be administered in the form of one or more pharmaceutical formulations, for example, mixed with (e.g., pharmaceutically acceptable) adjuvants, diluents, or carriers, which may be selected with due regard to the intended route of administration (e.g., topical application to relevant mucous membranes (including lungs) or preferably skin) and standard pharmaceutical or other (e.g., cosmetic) practices. Such pharmaceutically acceptable carriers may be chemically inert to the active compound and may be free of harmful side effects or toxicity under the conditions of use. Such pharmaceutically acceptable carriers may also impart immediate release or regulated release of the active ingredient.
[0207] Suitable pharmaceutical formulations may be commercially available or otherwise prepared according to techniques described in the literature, such as Remington The Science and Practice of Pharmacy, 22nd edition, Pharmaceutical Press (2012) and Martindale-The Complete Drug Reference, 38th edition, Pharmaceutical Press (2014) and the documents mentioned therein, the relevant disclosures of which are incorporated herein by reference. In other respects, the skilled person may non-inventively achieve the preparation of suitable formulations comprising the compounds of the invention using conventional techniques.
[0208] The compounds of the invention may be in the form of an aqueous formulation such as an emulsion, suspension and / or solution (e.g., an (optionally) buffered aqueous formulation (e.g., solution), such as a saline-containing formulation (e.g., solution), a phosphate-containing formulation (e.g., solution), an acetate-containing formulation (e.g., solution) or a borate-containing formulation (e.g., solution)) or a lyophilized powder.
[0209] The active ingredients may further and / or in the alternative be combined with suitable excipients to prepare:
[0210] Gel formulations (for which suitable gel matrix materials include cellulose derivatives, carbomers and alginates, tragacanth, gelatin, pectin, carrageenan, gellan gum, starch, xanthan gum, cationic guar gum, agar, non-cellulosic polysaccharides, sugars such as glucose, glycerol, propylene glycol, vinyl polymers, acrylic resins, polyvinyl alcohol, carboxyvinyl polymers, and in particular hyaluronic acid);
[0211] Lotions (for which suitable base materials include cellulose derivatives, glycerol, non-cellulose polysaccharides, polyethylene glycols of varying molecular weights, and propylene glycol);
[0212] Paste or ointment (for the paste or ointment, suitable paste base materials include glycerin, vaseline, paraffin, polyethylene glycol of different molecular weights, etc.);
[0213] Creams or foams (for the creams or foams, suitable excipients (e.g., foaming agents) include hydroxypropyl methylcellulose, gelatin, polyethylene glycols of different molecular weights, sodium lauryl sulfate, sodium fatty alcohol polyoxyethylene ether sulfonate, corn gluten powder, and acrylamide);
[0214] Powder aerosols (for which suitable excipients include mannitol, glycine, dextrin, dextrose, sucrose, lactose, sorbitol and polysorbates, e.g., dry powder inhalers); and / or
[0215] Liquids for oral use or for inhalation, such as aqueous (aerosol) sprays (for which suitable excipients include viscosity modifiers such as hyaluronic acid, sugars such as glucose and lactose, emulsifiers, buffers, alcohols, water, preservatives, sweeteners, flavoring agents, etc.);
[0216] Injectable solutions or suspensions (the injectable solutions or suspensions may be aqueous or otherwise, and suitable excipients for the injectable solutions or suspensions include solvents and cosolvents, solubilizers, wetting agents, suspending agents, emulsifiers, thickening agents, chelating agents, antioxidants, reducing agents, antimicrobial preservatives, buffers and / or pH regulators, fillers, protective agents and tonicity regulators).
[0217] Where appropriate, such formulations may also include humectants such as glycerol, glycerin, polyethylene glycol, trehalose, glycerol, petrolatum, paraffin oil, silicone oil, hyaluronic acid and its salts (e.g., sodium and potassium salts), octanoic / caprylic triglycerides, etc.; and / or antioxidants such as vitamins and glutathione; and / or pH adjusters such as acids, bases and pH buffers. In addition, surfactants / emulsifiers such as cetyl alcohol (cetyl alcohol), fatty acids (e.g., stearic acid), sodium dodecyl sulfate (sodium lauryl sulfate), sorbitan esters (e.g., sorbitan stearate, sorbitan oleate, etc.), monoacylglycerides (such as glyceryl monostearate) polyethoxylated alcohols, polyvinyl alcohol, polyol esters, polyoxyethylene alkyl ethers (e.g., polyoxyethylene sorbitan monooleate), polyoxyethylene castor oil derivatives, ethoxylated fatty acid esters, polyoxyglycerol esters, lauryl dimethylamine oxide, bile salts (e.g., sodium deoxycholate, sodium cholate), phospholipids, N,N-dimethyldodecylamine-N-oxide, cetyltrimethylammonium bromide, poloxamer, lecithin, sterols (e.g., cholesterol), sugar esters, polysorbates, etc.; preservatives such as phenoxyethanol, ethylhexylglycerol, etc.; and thickeners such as acryloyldimethyltaurate / VP copolymers. Specifically, especially in cream formulations, stearic acid, glyceryl monostearate, cetyl alcohol, sorbitan stearate, cetyl alcohol, caprylic / capric glycerides and the like may be included.
[0218] The compounds of the present invention and (for example, medicine) formulations (for example, aqueous solution, gel, cream, ointment, lotion, foam, paste and / or dry powder as described above) comprising them can be further combined with suitable host materials to prepare dressings or therapeutic patches for application on biological surfaces (such as skin or mucosal surfaces). Therefore, such preparations can be used to impregnate host materials, such as gauze, nonwovens or silk paper (silk paper). Alternatively, therapeutic patches can be, for example, band-aids, facial masks, eye masks, hand masks, foot masks, etc.
[0219] Petrolatum can be used to apply such dressings to wounds, but we have also found that a PEG (eg, PEG 400) based ointment can be combined with a matrix material to prepare a dressing without the use of petrolatum.
[0220] The compounds of the invention can be administered by inhalation of a suspension, dry powder or solution. Suitable inhalation devices include pressurized metered dose inhalers (pMDIs) (the pressurized metered dose inhalers can be manually actuated or breath-actuated and can be used with or without a standard spacer device), dry powder inhalers (DPIs) (the DPIs can be single-dose, multi-dose and power-assisted), and soft mist inhalers (SMIs) or nebulizers (wherein an aerosol in a fine mist is delivered at a slower speed than a spray delivered using a pMDI).
[0221] In a pMDI, the compounds of the invention may be administered as a pressurized suspension of micronized particles distributed in a propellant (e.g., HFA with excipients such as mannitol, lactose, sorbitol, etc.) or as an ethanol solution to deliver one or more metered doses between about 20 μL and about 100 μL per actuation. Actuation may be performed manually (e.g., by pressing) or by inhalation (breath actuation), involving a flow trigger system driven by a spring.
[0222] In a DPI, the compounds of the invention can be administered in the form of micronized drug particles (between about 1 μm and about 5 μm in size) within a capsule, either alone or blended with larger particle size inactive excipients (e.g., mannitol), which can be preloaded or manually loaded into the device. Inhalation from the DPI can deagglomerate the drug particles and disperse them within the airways.
[0223] In an SMI, the compound of the invention may be stored as a solution in a cartridge that is loaded into the device. A spring may release a dose into the micropump so that the dose is released when a button is pressed, thereby releasing a jet of drug solution.
[0224] Various nebulizers can also be used to administer the compounds of the present invention in the form of a fine mist of an aerosolized solution. Nebulizers can include breath-enhanced jet nebulizers (wherein, with the assistance of a compressor, an air stream moves through a jet, causing the drug solution to be aerosolized); breath-actuated jet nebulizers (wherein, after the patient inhales, with the assistance of a compressor, an air stream moves through a tube, causing the drug solution to be aerosolized); ultrasonic nebulizers (wherein a piezoelectric crystal vibrates, causing aerosolization by heating, thereby causing spraying); vibrating mesh nebulizers (wherein a piezoelectric crystal vibrates a mesh plate, causing aerosolization to give very fine droplets, and the temperature of the solution does not change significantly during the spraying process).
[0225] According to a further aspect of the present invention there is provided a process for the preparation of a pharmaceutical composition / formulation as defined herein, said process comprising bringing into association a compound of the invention as defined above and one or more pharmaceutically acceptable excipients as defined above.
[0226] The compounds of the invention may also be combined in therapy with one or more growth factors selected from platelet-type growth factors (including platelet-derived growth factor, PDGF); osteosarcoma-derived growth factor (ODGF), epidermal growth factor (EGF), transforming growth factor (TGFα and TGFβ), fibroblast growth factor (αFGF, βFGF), insulin-like growth factor (IGF-I, IGF-II), nerve growth factor (NGF), interleukin-type growth factors (IL-1, IL-1, IL-3), erythropoietin (EPO), and colony stimulating factor (CSF).
[0227] According to another aspect of the present invention, a (e.g., pharmaceutical) composition is provided, comprising the compounds of this invention and one or more pharmaceutically acceptable excipients, such as adjuvants, diluents or carriers. Preferred formulations are suitable for topical application to, for example, mucosa (including oral mucosa and / or nasal mucosa, lungs, anorectal region and / or colon) or more preferably skin, and therefore comprise an externally acceptable adjuvant, diluent or carrier.
[0228] Thus, further provided are pharmaceutical compositions comprising a compound of the invention suitable, adapted and / or packaged and presented for topical administration (e.g., to mucous membranes, including oral and / or nasal mucosa, lungs, anorectal region and / or colon, or preferably to the skin), and the use of such formulations in the treatment of disorders comprising inflammation, inflammatory disorders and / or conditions characterized by inflammation (e.g., as a symptom) by direct topical administration of the formulations (e.g., to mucous membranes, including oral and / or nasal mucosa, lungs, anorectal region and / or colon, or preferably to the skin).
[0229] With respect to this aspect of the invention, for the avoidance of doubt, topical formulations comprising the compounds of the invention may be used for any and all conditions described herein, including (as mentioned, defined or described above) in the treatment of any and all inflammatory disorders and / or in the treatment of any and all disorders characterized by inflammation to treat inflammation. Similarly, topical formulations comprising the compounds of the invention that may be mentioned include any and all of those mentioned, defined or described herein. Any and all of the relevant disclosures herein are hereby incorporated by reference in conjunction with this aspect of the invention.
[0230] Topical (e.g., liquid-based or (e.g., aqueous) solution-based formulations comprising a compound of the invention may be particularly useful for wound healing and may reduce pain (including dull pain) associated with the wound itself and the wound healing process, and in particular pruritus / itching. Such topical formulations comprising a compound of the invention may be particularly useful for preventing and / or inhibiting exudation of body fluids from wounds, particularly during the acute inflammatory phase, e.g., within the first 48 hours after incurring a burn or wound. This may prevent the risk of infection and other physiological reactions. Such topical formulations comprising a compound of the invention may also be particularly useful for preventing and / or inhibiting scarring and melanin deposition (see above), whether wound-related or otherwise.
[0231] Administration of the active ingredient may be continuous or intermittent. The mode of administration may also be determined by the timing and frequency of administration, but in the case of therapeutic treatment of inflammation also depends on the severity of the condition.
[0232] Depending on the disorder and patient to be treated and the route of administration, the compounds of the invention may be administered to a patient in need thereof at varying therapeutically effective doses.
[0233] Similarly, the amount of active ingredient in a formulation will depend on the severity of the condition and the patient to be treated, but can be determined by the skilled artisan.
[0234] In any case, a medical practitioner or other technical staff will be able to routinely determine the actual dosage that will be most suitable for an individual patient, which will depend on the severity of the condition and the route of administration. The dosages mentioned herein are illustrative of average cases; there may of course be individual cases where higher or lower dosage ranges are warranted and they are within the scope of the invention.
[0235] Doses may be administered between one and four times (eg, three times) per day.
[0236] Suitable concentrations of the compounds of the invention in aqueous solution products may be from about 0.01 mg / mL (eg, about 0.1 mg / mL) to about 15.0 mg / mL, calculated in all cases as the free (non-salt) compound.
[0237] In all cases, suitable topical dosages of the compounds of the present invention are in the range of about 0.05 μg to about 50 μg / cm2 calculated as the free (non-salt) compound. 2 Treatment area, such as about 0.1 μg (e.g., about 0.5 μg) to about 20 μg / cm 2 Treatment area, including about 1 μg to about 10 μg / cm 2 Treatment area, such as about 5 μg / cm 2 within the treatment area.
[0238] Suitable doses of the compounds of the invention for nasal administration (e.g., by inhalation) are in the range of about 0.01 μg to about 2000 mg, for example, between about 0.1 μg to about 500 mg or between 1 μg to about 100 mg. Specific doses for nasal administration that may be mentioned include doses between about 10 μg to about 1 mg, in particular about 0.1 mg (i.e., about 100 μg). It has been found that in the treatment of conditions associated with inflammation of the nasal passages and mucous membranes, such as rhinitis (e.g., allergic rhinitis), daily nasal administration of about 0.1 mg of the compounds of the invention is particularly effective.
[0239] Suitable doses of the compounds of the invention for pulmonary administration (e.g., by inhalation) are in the range of about 0.01 μg to about 2000 mg, for example, between about 0.1 μg to about 500 mg or between 1 μg to about 100 mg. Specific doses for pulmonary administration that may be mentioned include between about 10 μg to about 10 mg, in particular about 0.6 mg (i.e., 60 μg) to 6 mg (e.g., for the treatment of COPD or idiopathic pulmonary fibrosis).
[0240] We prefer that formulations comprising compounds of the invention have a pH in the range of about 1.0 to about 9.0 (eg, about 3.0 to about 8.0).
[0241] In any case, in the context of the present invention, the dose administered to a mammal, particularly a human, should be sufficient to produce a therapeutic response (as described above) in the mammal within a reasonable time frame. Those skilled in the art will recognize that the selection of the exact dose and composition and the most appropriate delivery regimen will also be affected, among other things, by the pharmacological properties of the formulation, the nature and severity of the condition being treated, and the physical condition and mental acuity of the recipient, as well as the age, condition, weight, sex and response of the patient to be treated, and the stage / severity of the disease, as well as genetic differences between patients.
[0242] In the uses and methods described herein, the compounds of the invention may also be combined with one or more active ingredients (other anti-inflammatory agents) that can be used to treat inflammation and / or inflammatory disorders. Thus, such patients may also (and / or have) been receiving therapy based on administration of one or more such other active ingredients, by which we mean receiving a prescribed dose of one or more of those active ingredients mentioned herein before, simultaneously with, and / or after treatment with the compounds of the invention.
[0243] Such anti-inflammatory agents that can be used in combination with the compounds of the invention in the treatment of inflammation include therapeutic agents useful for treating inflammation and / or diseases characterized by inflammation as one of their symptoms. Depending on the condition to be treated, such anti-inflammatory agents can include NSAIDs, leukotriene receptor antagonists (e.g., montelukast itself), corticosteroids, analgesics, and certain enzymes (such as trypsin), for example as described below. The compounds of the invention can also be combined with leukotriene B4 (LTB4).
[0244] In this context, the compounds of the invention may also be used in combination with one or more mussel adhesive proteins (MAPs) for the treatment of inflammation, including any adhesive protein that may be derived from a mussel species, such as Mytilus edulis (blue mussel), including full-length proteins derived or that may be derived from mussels, including all isoforms, such as collagens pre-COL-P, pre-COL-D and pre-COL-NG, mussel foot matrix proteins PTMP and DTMP, and more preferably mfps or mefps (such as mefp-2, mefp-3, mefp-4, mefp-5, mefp-6, and especially mefp-1), and including mixtures or combinations of any of these proteins (such as mefps). Naturally occurring MAP can be prepared, for example, by mixed adsorption chromatography (see Chinese Patent No. ZL200710179491.0), by carboxymethyl ion exchange chromatography (see Chinese Patent No. ZL200710179492.5), and / or by salting out and dialysis (Chinese Patent No. ZL200910087567.6). Commercial sources of MAP include USUN BioCo. (China; as MAP MAP (sold by ), BD Biosciences (USA), Kollodis (South Korea), and Biopolymer (Sweden). Alternatively, MAP can be produced using known recombinant DNA methods.
[0245] Derivatives of MAP (e.g., pharmaceutically acceptable derivatives) may also be combined with the compounds of the invention, and include compounds having a molecular weight, for example, in the range of about 500 Da to about 2,000 Da (e.g., about 1,500 Da, such as about 1,200 Da, including about 800 Da). Such derivatives may also include other compounds comprising an amino acid sequence identical to a sequence identified in a naturally occurring MAP or as a (e.g., minor) variant thereof (as defined above), and the other compounds may be synthesized by chemical and / or biological methods (e.g., chemical modification or direct synthesis of a naturally occurring MAP).
[0246] For example, as discussed above, an isolated decapeptide compound having the following sequence:
[0247] Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Lys (mefp-1 decapeptide, SEQ ID No: 4); and
[0248] Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Lys (SEQ ID No: 12)
[0249] It is a pharmaceutically acceptable low molecular weight MAP derivative that can be combined with the compounds of the present invention.
[0250] Other preferred agents that may be combined with the compounds of the invention include LTB4 (used in the treatment of wounds and burns), montelukast (generally used in the treatment of inflammation), and trypsin (used in the treatment of mucosal inflammation associated with, for example, viral infections).
[0251] The compounds of the invention may also be combined with other therapeutic agents that are known to produce inflammation as a side effect when administered.
[0252] When a compound of the invention may be "combined" with other therapeutic agents in this manner, the active ingredients may be administered together in the same formulation or separately (either simultaneously or sequentially) in different formulations.
[0253] Such combination products provide for combined administration of a compound of the invention and an additional therapeutic agent, and thus may be presented as separate formulations, wherein at least one of these formulations contains the compound of the invention and at least one contains the additional therapeutic agent, or may be presented (i.e., formulated) as a combined preparation (i.e., presented as a single formulation containing the compound of the invention and the additional therapeutic agent).
[0254] Therefore, it is further provided that:
[0255] (1) a pharmaceutical formulation comprising a compound of the invention; another anti-inflammatory agent, or an agent known to produce inflammation as a side effect; and a pharmaceutically acceptable excipient (e.g., an adjuvant, diluent or carrier), said formulation being hereinafter referred to as a "combination preparation"; and
[0256] (2) A kit comprising the following components:
[0257] (A) a pharmaceutical formulation comprising a compound of the invention in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier; and
[0258] (B) a pharmaceutical formulation comprising another anti-inflammatory agent or an agent known to produce inflammation as a side effect, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier,
[0259] The components (A) and (B) are each provided in a form suitable for administration in combination with one another.
[0260] In a further aspect of the invention there is provided a process for the preparation of a combined preparation as defined above, the process comprising associating a compound of the invention, another anti-inflammatory agent or an agent known to produce inflammation as a side effect, and at least one (e.g. pharmaceutically acceptable) excipient.
[0261] In a further aspect of the invention there is provided a method for preparing a kit as defined above, the method comprising associating components (A) and (B). As used herein, reference to association will mean making the two components suitable and administered in combination with each other.
[0262] Thus, with respect to a method for preparing a kit as defined above by bringing two components "into association" with each other, we include that the two components of the kit may:
[0263] (i) are provided as separate formulations (i.e., separate from each other) which are subsequently brought together for use in combination with each other in a combination therapy; or
[0264] (ii) The individual components are packaged together and presented as a "combination pack" for use in combination with each other in a combination therapy.
[0265] Therefore, a kit is further provided, comprising:
[0266] (I) one of components (A) and (B) as defined herein; and
[0267] (II) Instructions for using the component in combination with the other of the two components.
[0268] To provide repeated doses, the kits described herein may include more than one formulation containing an appropriate amount / dose of a compound of the invention, and / or more than one formulation containing an appropriate amount / dose of another anti-inflammatory agent. If more than one formulation (containing any one active compound) is present, such formulations may be the same or may differ in terms of the dose of the compound, one or more chemical compositions, and / or one or more physical forms.
[0269] With respect to the kit as described herein, by "administering in combination with" we mean that the corresponding formulations comprising the compound of the present invention and the other anti-inflammatory agent are administered sequentially, separately and / or simultaneously during the treatment of the relevant condition.
[0270] Thus, with respect to the combination products according to the invention, the term "administered in combination with" includes that the two components of the combination product (the compound of the invention and the other anti-inflammatory agent) are administered together or sufficiently close in time (optionally repeatedly) to enable the patient to experience a beneficial effect in the treatment of the relevant condition that is greater than if the formulation containing the compound of the invention or the formulation containing the other agent were administered separately (optionally repeatedly) in the absence of the other component in the same treatment. The determination of whether the combination provides a greater beneficial effect with respect to a specific condition and in its treatment will depend on the condition to be treated or prevented, but can be routinely accomplished by the skilled person.
[0271] Furthermore, in the context of the kit according to the invention, the term "in combination with" includes that the two formulations can be administered (optionally repeatedly) before, after and / or simultaneously with the administration of the other component. When used in this context, the terms "administered simultaneously" and "administered simultaneously with" include that separate doses of the relevant compound of the invention and the other anti-inflammatory agent are administered within 48 hours (e.g., 24 hours) of each other.
[0272] Wherever the word "about" is used herein (e.g., in the context of an amount such as concentration and / or dosage of an active ingredient, molecular weight, or pH), it will be appreciated that such variables are approximate and may therefore vary by ±10%, e.g., ±5%, and preferably ±2% (e.g., ±1%) relative to the number specified herein. In this regard, the term "about 10%" means, for example, ±10% with respect to the number 10, i.e., between 9% and 11%.
[0273] The compounds of the invention have the advantage that they can be used in a variety of conditions characterised by inflammation, whether the condition is an organ inflammatory disease per se or is associated with or characterised by inflammation (eg wounds, burns or viral infections).
[0274] The uses and methods described herein may also have the following advantages: in the treatment of the above-mentioned conditions, they may be more convenient for the physician and / or the patient, more effective, less toxic, have a broader spectrum of activity, be more potent, produce fewer side effects, or it / they may have other useful pharmacological properties compared to similar compounds or methods (treatments) known in the prior art, whether for the treatment of inflammation, inflammatory disorders or disorders characterized by inflammation as a symptom (including wounds) or otherwise.
[0275] The present invention is illustrated by the following examples, wherein for various compounds including the compounds of the present invention, Figure 1 The swelling rate in the mouse ear swelling model is shown; Figure 2 shows the Hyp content (and therefore the level of recovery), and Figure 3 The levels of vascular endothelial growth factor and transforming growth factor-β1 in wound tissue in an acute wound mouse model are shown; Figure 4 The rate of unhealed wounds is shown. Figure 5 Skin regeneration is shown, and Figure 6 Fibroblast proliferation scores in a diabetic wound mouse model are shown; Figure 7 The ratio of the remaining wound area to the initial wound area is shown. Figures 8 to 11 The results of histopathological analysis in terms of various wound healing markers (skin regeneration, fibroblast proliferation, inflammation and Masson staining, respectively) are shown, and Fig.12 The edema levels in different groups in an additional diabetic wound model are shown; Fig.13 and Fig.17 Both show the effect of the compounds of the invention on edema caused by acute inflammation in another mouse ear swelling model; Fig.14 The rates of non-healed wounds in an additional acute wound mouse model are shown; Fig.15 A comparison between compounds of the invention and known anti-inflammatory steroids in a mouse ear swelling model is shown; and Fig.16 Shown is the IL-1β content in lung tissue for different compounds of the present invention in a mouse lung injury model. Example
[0276] Example 1
[0277] Montelukast styrene-Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Lys (i.e., at the N-terminus Synthesis of Montelukast (styrene) covalently bonded to the amino acid SEQ ID No: 12
[0278] To synthesize 3 mmol of peptide SEQ ID No: 12, the following procedure was followed.
[0279] Fmoc-Lys-Boc-Wang resin (9.15 g, GLS180322-41301, GL Biochem, Shanghai, China) was loaded into a glass reaction column.
[0280] Dichloromethane (DCM, 200 mL; Shandong Jinling Chemical Industry Co Ltd, Shandong, China) was added to the column and the resin was allowed to soak for about half an hour. The DCM was then removed by vacuum filtration.
[0281] The resin was washed with N,N-dimethylformamide (DMF, 200 mL; Shandong Shitaifeng Fertilizer Industry Co Ltd, Shandong, China) three times.
[0282] A 20% piperidine solution in DMF (200 mL; Shandong Shitaifeng Fertilizer Industry Co Ltd, Shandong, China) was added as a deprotection solution and reacted for 20 minutes. The solution was then removed by vacuum filtration and the column was washed six times with DMF.
[0283] Fmoc-Tyr(tBu)-OH (4.14 g; GLS170916-36901, GL Biochem, Shanghai, China) and 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylamine tetrafluoroborate (TBTU, 2.89 g; GLS170805-00705, GLBiochem, Shanghai, China) were added to the resin. DMF (150 mL) was added to the reaction column, followed by N,N-diisopropylethylamine (DIPEA, 2.33 g; Suzhou Highfine Biotech Co. Ltd, Jiangsu, China). A color reaction was detected in the resin after 30 minutes, indicating that the reaction was complete. The solvent was removed by vacuum filtration.
[0284] The above coupling steps were repeated to couple the same amounts (by mole) of the remaining amino acids: Fmoc-Thr(tBu)-OH, Fmoc-4-Hyp(tBu)-OH, Fmoc-4-Hyp(tBu)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Pro-OH, Fmoc-Lys(Boc)-OH and Fmoc-Ala-OH.
[0285] Finally, montelukast (5.47 g; MedChemExpress, MCE China, Shanghai, China) was added to the resin. The liquid was then drained after 15 minutes and washed 3 times each with DMF, DCM and methanol.
[0286] 91.5mL (i.e., 10mL / gram of resin) lysate is added to submerge the peptide compound bound to the resin, and the lysate is composed of 95% trifluoroacetic acid (TFA), 2.5% water and 2.5% triisopropylsilane (Tis). In the cleavage process, the side chain is also deprotected. After the cleavage, the solid support is removed by filtration and the filtrate is concentrated under reduced pressure. The peptide of the ether precipitation cracking and lyophilization are used to produce 600mg of the thick title compound.
[0287] 1 mg of crude product was dissolved in 1 mL of a mixture of acetonitrile and water (1:3) and detected using a P3000A HPLC pump and a LC3000 semi-preparative device (preparative column model: GS-120-10-C18-AP 30 mm; Beijing Chuangxintongheng Science & Technology Co., Ltd., Beijing, China). An appropriate elution gradient was calculated and the target peak was detected at 11.035 using LCMS (analytical column model: GS-120-5-C18-BIO, 4.6*250 mm; detection: UV at 220 nm; solvent A: 0.1% TFA in MeCN, solvent A: 0.1% TFA in water; flow rate: 1.0 mL / min; volume: 10 μL).
[0288] The crude compound was desalted using anion exchange resin, analyzed and freeze dried. Approximately 50 mg of purified peptide was obtained after purification and was retested for confirmation.
[0289] MS: m / z 866.90[M+2H] 2+ .
[0290] Based on the characterization data available and presented herein, it is understood that the compound prepared by this example is the compound identified above as the title compound. In addition, the compound prepared in Example 1 is a compound of the present invention, wherein in the compound of Formula I, n is 0 and the compound of Formula I is covalently bonded to the amino acid SEQ ID No: 12 at the N-terminus. In any case, the compound of Example 1 is hereinafter referred to as "Compound A".
[0291] Example 2
[0292] Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Lys (Montelukast styrene) (i.e., at the C-terminus Synthesis of montelukast styrene covalently bonded to the amino acid SEQ ID No: 4
[0293] A procedure similar to that described in Example 1 above was used starting from Fmoc-Lys(Dde)-OH (CAS No: 150629-67-7) on Wang resin.
[0294] A 25% piperidine solution in DMF (200 mL; Shandong Shitaifeng Fertilizer Industry Co Ltd, Shandong, China) was added to remove the protective Fmoc group.
[0295] The second protected amino acid, Fmoc-DOPA(acetonide)-OH, was added, along with TBTU and DIPEA until the reaction was complete.
[0296] The above coupling steps were repeated to couple the same amounts (by mole) of the remaining amino acids: Fmoc-Thr(tBu)-OH, Fmoc-4-Hyp(tBu)-OH, Fmoc-4-Hyp(tBu)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Pro-OH, Fmoc-Lys(Boc)-OH and Fmoc-Ala-OH.
[0297] The peptidyl-resin was placed in a flask and treated with 2% hydrazine monohydrate (25 mL / g) in DMF. The flask was stoppered and the mixture was allowed to stand at room temperature for 3 minutes. The resin was then washed with DMF. Montelukast (5.47 g; MedChemExpress, MCE China, Shanghai, China) was added to the resin along with TBTU and DIPEA and the mixture was reacted for 1 hour.
[0298] The protected peptidyl-resin was treated with 91.5 mL of lysate (a mixture of 95% TFA, 2.5% water and 2.5% Tis) for 1 hour. After cleavage, the solid support was removed by filtration and the filtrate was concentrated under reduced pressure. The cleaved peptide was precipitated with ether and lyophilized to produce approximately 600 mg of the crude title compound.
[0299] After purification, 50 mg of pure product was obtained.
[0300] MS: m / z 875.75[M+2H] 2+ .
[0301] Based on the characterization data available and presented herein, it is understood that the compound prepared by this example is the compound identified above as the title compound. In addition, the compound prepared in Example 2 is a compound of the present invention, wherein in the compound of Formula I, n is 0 and the compound of Formula I is covalently bonded to the amino acid SEQ ID No: 4 on the C-terminal Lys. In any case, the compound of Example 2 is hereinafter referred to as "Compound B".
[0302] Example 3
[0303] Montelukast styrene-Ala-Lys-Pro-pSer-Tyr-Hyp-Hyp-Thr-Tyr-Lys (i.e., at the N-terminus Synthesis of Montelukast (styrene) covalently bonded to the amino acid SEQ ID No: 13
[0304] A procedure similar to that described in Example 4 below was used starting from Fmoc-Lys(Dde)-OH (CAS No: 150629-67-7) on Wang resin.
[0305] A 25% piperidine solution in DMF (200 mL; Shandong Shitaifeng Fertilizer Industry Co Ltd, Shandong, China) was added to remove the protective Fmoc group.
[0306] The second protected amino acid Fmoc-Tyr(tBu)-OH (GLS170916-36901, GL Biochem, Shanghai, China) was added, along with ByBOP and DIPEA until the reaction was complete.
[0307] The above coupling steps were repeated to couple the same amounts (by mole) of the remaining amino acids: Fmoc-Thr(tBu)-OH, Fmoc-4-Hyp(tBu)-OH, Fmoc-4-Hyp(tBu)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-pSer(tBu)-OH, Fmoc-Pro-OH, Fmoc-Lys(Boc)-OH and Fmoc-Ala-OH.
[0308] The peptidyl-resin was placed in a flask and treated with 2% hydrazine monohydrate (25 mL / g) in DMF. The flask was stoppered and the mixture was allowed to stand at room temperature for 3 minutes. The resin was then washed with DMF. Montelukast (1.8 g; MedChemExpress, MCE China, Shanghai, China) was added to the resin along with TBTU and DIPEA and the mixture was reacted for 1 hour.
[0309] Lysate (10 mL / gram of resin) was added to submerge the peptide-containing compound bound to the resin, which was composed of 95% trifluoroacetic acid (TFA), 2.5% water, and 2.5% triisopropylsilane (Tis). During the cleavage process, the side chains were also deprotected. After cleavage, the solid support was removed by filtration and the filtrate was concentrated under reduced pressure. The cleaved peptide was precipitated with ether and lyophilized to produce 1.4 g of crude peptide.
[0310] 1 mg of crude product was dissolved in 1 mL of a mixture of acetonitrile and water (1:3) and detected using a P3000A HPLC pump and a LC3000 semi-preparative device (preparative column model: GS-120-10-C18-AP 30 mm; Beijing Chuangxintongheng Science & Technology Co., Ltd., Beijing, China). An appropriate elution gradient was calculated and the target peak was detected using LCMS (analytical column model: GS-120-5-C18-BIO, 4.6*250 mm).
[0311] The crude compound was desalted using anion exchange resin, analyzed and freeze dried and retested for confirmation.
[0312] After purification, 98 mg of pure product were obtained (yield about 7% from the crude product).
[0313] MS: m / z 907.3[M+2H] 2+ .
[0314] Based on the characterization data available and presented herein, it is understood that the compound prepared by this example is the compound identified above as the title compound. In addition, the compound prepared in Example 3 is a compound of the present invention, wherein in the compound of Formula I, n is 0 and the compound of Formula I is covalently bonded to the amino acid SEQ ID No: 13 at the N-terminus. In any case, the compound of Example 3 is hereinafter referred to as "Compound C".
[0315] Example 4
[0316] Ala-Lys(Montelukast Phenyl)-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Lys(Montelukast Phenyl) Synthesis of montelukast styrene (i.e., two montelukast styrene molecules covalently bonded to the amino acid SEQ ID No: 12 via a Lys residue)
[0317] To synthesize 1 mmol of peptide SEQ ID No: 12, the following procedure was followed.
[0318] Fmoc-Lys(Dde)-OH on Wang resin (CAS No.: 150629-67-7) (3 g, GL Biochem, Shanghai, China) was loaded into a glass reaction column.
[0319] Dichloromethane (DCM, 60 mL; Shandong Jinling Chemical Industry Co Ltd, Shandong, China) was added to the column and the resin was allowed to soak for about half an hour. The DCM was then removed by vacuum filtration.
[0320] The resin was washed with N,N-dimethylformamide (DMF, 60 mL; Shandong Shitaifeng Fertilizer Industry Co Ltd, Shandong, China) three times.
[0321] A 20% piperidine solution in DMF (30 mL; Shandong Shitaifeng Fertilizer Industry Co Ltd, Shandong, China) was added as a deprotection solution and reacted for 20 minutes. The solution was then removed by vacuum filtration and the column was washed six times with DMF.
[0322] Fmoc-Tyr(tBu)-OH (1.4 g; GLS170916-36901, GL Biochem, Shanghai, China) and benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (ByBOP, 1.56 g; Suzhou Highfine Biotech Co. Ltd, Jiangsu, China) were added to the resin, followed by DIPEA (1 mL; Suzhou Highfine Biotech Co. Ltd, Jiangsu, China). A color reaction was detected in the resin after 30 minutes, indicating that the reaction was complete. The solvent was removed by vacuum filtration.
[0323] The above coupling steps were repeated to couple the same amounts (by mole) of the remaining amino acids: Fmoc-Thr(tBu)-OH, Fmoc-4-Hyp(tBu)-OH, Fmoc-4-Hyp(tBu)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Pro-OH, Fmoc-Lys(Dde)-OH and Boc-Ala-OH.
[0324] The peptidyl-resin was placed in a flask and treated with 2% hydrazine monohydrate (25 mL / g) in DMF. The flask was stoppered and the mixture was allowed to stand at room temperature for 3 minutes. The resin was then washed with DMF. Montelukast (3.6 g; MedChemExpress, MCE China, Shanghai, China) was added to the resin along with TBTU and DIPEA and the mixture was reacted for 1 hour.
[0325] Lysate (30 mL; 10 mL / gram of resin) was added to submerge the peptide-containing compound bound to the resin, which consisted of 95% trifluoroacetic acid (TFA), 2.5% water, and 2.5% triisopropylsilane (Tis). During the cleavage process, the side chains were also deprotected. After cleavage, the solid support was removed by filtration and the filtrate was concentrated under reduced pressure. The cleaved peptide was precipitated with ether and lyophilized to produce 1.6 g of crude peptide.
[0326] 1 mg of crude product was dissolved in 1 mL of a mixture of acetonitrile and water (1:3) and detected using a P3000A HPLC pump and a LC3000 semi-preparative device (preparative column model: GS-120-10-C18-AP 30 mm; Beijing Chuangxintongheng Science & Technology Co., Ltd., Beijing, China). An appropriate elution gradient was calculated and the target peak was detected using LCMS (analytical column model: GS-120-5-C18-BIO, 4.6*250 mm).
[0327] The crude compound was desalted using anion exchange resin, analyzed and freeze dried and retested for confirmation. 20 mg of purified peptide (90-95% purity) was obtained from 1.6 g of crude peptide.
[0328] MS: m / z 762.2[M+3H] 3+ .
[0329] Based on the characterization data available and presented herein, it is understood that the compound prepared by this example is the compound identified above as the title compound. In addition, the compound prepared in Example 4 is a compound of the present invention, wherein in the compound of Formula I, n is 0 and the compound of Formula I is covalently bonded to the amino acid SEQ ID No: 12 via a Lys residue. In any case, the compound of Example 4 is hereinafter referred to as "Compound D".
[0330] Example 5
[0331] Mouse ear swelling model I
[0332] 35 healthy male BALB / c mice of 6-8 weeks old and average body weight of 18-25g provided by Changzhou Cvens Experimental Animal Co.Ltd. were housed and cared for about 1 week before the experiment. The house temperature was 25°C-27°C, with 74% humidity, 12-hour cycles of light and darkness alternating, and free access to food and water. The mice were randomly divided into 7 groups, as described in Table 1 below, with 5 mice in each group.
[0333] The left ear of each mouse was used as an autologous control. The right ear of each mouse was treated with various treatments, as summarized in Table 1 below. 20 μL of xylene (Shanghai Aladdin Bio-Chem Technology Co., Ltd., Shanghai, China) was applied to both the inside and outside of the right ear of each mouse. In about 4 minutes, the ear began to swell. Then, 0.08 g of each study treatment or vehicle was applied to the right ear of each group. The mice were returned to their cages.
[0334] A montelukast sodium-based cream (Mon) was manufactured, consisting of the following components: montelukast sodium (200 mg; Arromax Pharmatech Co., Ltd., Suzhou, China), stearic acid (2 g), glyceryl monostearate (2 g), cetyl alcohol (2 g), glycerol (5 g) and sodium hydroxide (0.25 g) (all from Sinopharm Chemical Reagent Co., Ltd., Shanghai, China); ammonium acryloyldimethyltaurate / VP copolymer (0.13 g; Clariant Chemical (Guangzhou) Co., Ltd., Guangzhou, China); phenoxyethanol (0.3 g) and ethylhexylglycerin (0.1 g) (both from ShanghaiRayson Chemicals Co., Ltd., Shanghai, China); and purified water (88.42 g).
[0335] Stearic acid, glyceryl monostearate and cetyl alcohol were mixed and heated to 85° C. with stirring until the mixture was completely melted. Ammonium acryloyldimethyltaurate / VP copolymer, purified water and sodium hydroxide were mixed with stirring at 85° C. to form a uniform colloidal suspension. Montelukast sodium, glycerin, phenoxyethanol and ethylhexylglycerin were then combined with stirring until montelukast was completely dissolved.
[0336] The copolymer / water mixture was added to the mixture containing stearic acid and emulsified by rapid stirring for five minutes using an emulsifying device. The resulting emulsion was cooled to 55°C and the mixture containing montelukast was added under mixing. The resulting mixture was allowed to cool to room temperature to obtain the finished product.
[0337] Dexamethasone cream (DEX) was manufactured using the same procedure except that 0.4 mg of dexamethasone (Shanghai Aladdin Bio-Chem Technology Co., LTD, Shanghai, China) was used instead of montelukast.
[0338] A gel containing Compound A ("A gel") was prepared, consisting of the following components: 0.5 g of Compound A powder (obtained from GL Biochem, Shanghai, China; prepared as described in Example 1 above), methylcellulose (2.2 g; Shandong Guangda Technology Development Co., Ltd., Shandong, China), glycerol (11 g) and propylene glycol 11 g (both from Sinopharm Chemical Reagent Co. Ltd.), and purified water (75.3 g).
[0339] The methylcellulose and water were mixed together and stirred until a uniform colloidal suspension was formed. Compound A powder, glycerol and propylene glycol were then added to the methylcellulose / water mixture and the resulting mixture was rapidly stirred for 5 minutes to obtain the finished product.
[0340] An Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Lys-based gel (Compound 1 (SEQ ID No: 12); 1.5 g; obtained as a powder from GL Biochem, Shanghai, China and made by essentially the same method as described above in Example 1, without montelukast conjugated at the terminus) was made by the same method as described above for Compound A (“1 Gel”).
[0341] Vehicle-1 in Table 1 below is a cream base without active ingredients. Vehicle-2 in Table 1 below is a gel base without active ingredients. Both were made using the same procedure as described above, with no active ingredients added.
[0342] Table 1
[0343]
[0344]
[0345] Mice were sacrificed by cervical dislocation after 40 minutes. The left and right ears were cut off. Ear fragments were removed from the same part of both ears using a leather bag with a diameter of 8 mm (Electron Microscopy Sciences, Hatfield, Pennsylvania, USA). The weight was recorded and the swelling rate was calculated as follows:
[0346] Swelling rate = (right ear weight - left ear weight) / left ear weight × 100%
[0347] And the results are shown in Tables 2 and Figure 1 Shown in.
[0348] Table 2
[0349] Model Medium 1 Medium 2 Dex Cream Mon Cream Compound 1 Compound A 97.4 95% 97% 45% 38% 61.5% 55% 0.03 0.2 0.35 0.19 0.25 0.17 0.06
[0350] The above results showed that both tested compounds reduced xylene-induced swelling.
[0351] Example 6
[0352] Acute Wound Model I
[0353] 6-8 week old male C57BL / 6 mice were provided by Changzhou Cvens Experimental Animal Co. Ltd. Mice were housed under standard conditions (12-hour cycles of light and dark alternating at a constant temperature or 22±2° C.) and fed a standard mouse diet with water for approximately one week before any experiments were performed.
[0354] General anesthesia was induced using intraperitoneal 3% chloral hydrate (Sinopharm Chemical Reagent Co., Ltd.; 1 mL / 10 g body weight). The back hair was shaved with a baby shaver and depilated with cream. The skin area was wiped and sterilized twice with 75% alcohol.
[0355] A circular wound was made on the midline of the back using an 18 mm diameter EMS skin biopsy punch (Electron Microscopy Sciences, PO Box 550, 1560 Industry Road, Hatfield, PA 19440). The full thickness of the skin was removed and the depth reached the fascia. The wound was left open without suturing.
[0356] Different drugs were administered topically at 50 μL / wound once a day from day 0 to day 7. The model group was given the same amount of saline. There were 7 groups in this experiment, including 56 mice, as shown in Table 3 below.
[0357] Recombinant human epidermal growth factor (rhEGF, Shanghai Haohai Biological Technology Co. Ltd, Shanghai, China) was purchased and prepared according to the manufacturer's instructions. Lyophilized rhEGF powder (100000 IU / vial) was dissolved in 20 mL of normal saline to make a solution with a concentration of 5000 IU / mL. The working dose of rhEGF in this experiment was 1285 IU / wound.
[0358] Compound B was obtained as a powder from GL Biochem and prepared as described above in Example 2. Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Lys (Compound 2; SEQ ID No: 4) was obtained as a powder from GL Biochem and prepared essentially as described above in Example 2, but without montelukast conjugated at the terminal end. The powder was stored at -20°C and dissolved in saline at the concentrations indicated in Table 3 below (L and H indicate low and high doses, respectively).
[0359] Table 3
[0360]
[0361] Hydroxyproline (Hyp) is a non-proteinogenic amino acid found in collagen, which contains approximately 12%-14% Hyp by mass. Therefore, the Hyp content in tissue hydrolysate is a direct measure of the amount of collagen present, and the amount of Hyp present in wound tissue directly indicates the level of recovery. The Hyp content in each group was 2.34% on the 4th and 7th day after the start of treatment. Figure 2 Shown in.
[0362] The results showed that the test compounds improved the Hyp content of all treatment groups. Both lower doses of compound 2 and compound B showed effects at an early stage (day 4 (D4)). On day 7 (D7), higher doses of the two test compounds also showed an accelerated effect on Hyp production.
[0363] Vascular endothelial growth factor (VEGF) and transforming growth factor-β1 (TGF-β1) play an important role in the wound healing process. VEGF and TGF-β1 are often co-expressed in tissues where angiogenesis occurs. The levels of these two factors in wound tissues were also measured and Figure 3 Shown in.
[0364] The results showed that both peptides could stimulate the production of VEGF and TGF-β1.
[0365] Example 7
[0366] Diabetic Wound Model I
[0367] Similar experiments using essentially the same protocol as described in Example 6 above were performed on 8 to 12 week old male db / db mice (C57BL / KsJ-db / db) (Changzhou Cvens Experimental Animal Co. Ltd.) weighing 35-45 g / mouse.
[0368] An EMS skin biopsy punch with a diameter of 18 mm was used to create the wound.
[0369] Different drugs were topically administered at 50 μL / wound once a day from day 0 to day 12. The model group was given the same amount of normal saline. There were 7 groups in this experiment, including 52 mice, as shown in Table 4 below.
[0370] Table 4
[0371]
[0372] Pictures of each wound were taken every other day starting from day 0. The pictures were scanned into a computer and the wound area was calculated using ImageJ image analysis software (National Institute of Health, USA).
[0373] Unhealed wound area is expressed as a percentage of the original wound area:
[0374] A t / A0×100%,
[0375] Where A0 and A t Refers to the initial area on day 0 and the wound area on the measurement date (time t), respectively.
[0376] The rate of unhealed wounds Figure 4 The results show that compound A has the best effect on improving wound recovery and is better than the effect of the combination of compound 1 and montelukast.
[0377] Histological samples were analyzed, and skin regeneration score, fibroblast proliferation score, collagen regeneration score (Masson score), and inflammation score were estimated as follows.
[0378] HE and Masson-stained sections were observed under an optical microscope and scored according to the following criteria (1, 2, or 3 points). Skin regeneration was scored as 1 point when the new skin covered an area no greater than one-third of the wound area; 2 points when the new skin covered an area greater than one-third but less than two-thirds of the wound area; and 3 points when the new skin covered an area of at least two-thirds of the wound area.
[0379] Skin regeneration score Figure 5 Shown in.
[0380] Fibroblast proliferation was scored according to the following criteria and is presented in Figure 6 middle.
[0381]
[0382] Pathological analysis results showed that compound A and compound 1 could promote skin regeneration and fibroblast proliferation. The conjugate compound A was slightly better, especially in terms of fibroblast proliferation score.
[0383] Example 8
[0384] Diabetic Wound Model II
[0385] Similar experiments using essentially the same protocol as described in Example 7 above were performed on 8 to 12 week old male db / db mice (C57BL / KsJ-db / db) (Changzhou Cvens Experimental Animal Co. Ltd.) weighing 35-45 g / mouse.
[0386] Different concentrations of Compound A and Compound 1 (as indicated as "A" and "1", respectively, in Table 5 below) were prepared in substantially the same manner as described in Examples 6 and 7 above. Medium and low doses of montelukast sodium ("Mon" in Table 5 below; MedChemExpress, MCE China, Shanghai, China) were dissolved in ultrapure water to obtain solutions of concentrations as described in Table 5 below (L, M, and H indicate low dose, medium dose, and high dose, respectively). In view of the low solubility of montelukast in water, a high dose montelukast test sample was prepared by dissolving montelukast in 100% ethanol and then adding ultrapure water to form a solution with a concentration of 20 μg / μL in 20% ethanol.
[0387] Different drugs were topically administered once a day from day 0 to day 12 at 50 μL / wound, as shown in the following Table 5. The control group did not suffer from wounds.
[0388] Table 5
[0389]
[0390]
[0391] The model group was given the same amount of saline. There were 8 mice in each group. There were 4 mice in the control group. For the control group, on the 7th day, skin fragments taken during the wound formation process were used as samples.
[0392] The effects of the drugs on wound healing during the first 12 days are shown in Tables 6 and Figure 7 , where the ratio of the remaining wound area to the initial wound in the different groups is shown (± SD, in the case of Table 6).
[0393] Table 6
[0394]
[0395] The data showed that low doses of Compound 1 induced wound healing at an earlier stage after wound incurring and that medium doses of Compound A induced better results at a later stage.
[0396] Histological samples were analyzed as described in Example 7 above, except that the collagen deposition was scored as follows for Masson stained samples. Comparison was made with normal tissue. No clear blue staining was scored as 0 points; blue fibers that appeared in a scattered pattern were scored as 1 point; if more blue fibers appeared, they were scored as 2 points, and diffuse blue was scored as 3 points.
[0397] The results of histopathological analysis showed Figures 8 to 11 All treatment groups accelerated wound healing, especially the medium dose of compound A, which showed a significant promoting effect on collagen deposition.
[0398] The edema levels in the different groups were also evaluated by histopathological analysis and the results were Fig.12 The data show that a moderate dose of Compound A gave the best effect.
[0399] Example 9
[0400] Mouse ear swelling model II
[0401] A similar experiment was performed on 35 healthy male BALB / c mice using a protocol essentially identical to that described above in Example 5. The mice were randomly divided into 7 groups, as described in Table 7 below, with 5 mice in each group.
[0402] Compounds A, B, C and D were obtained from GL Biochem Ltd.
[0403] In the following Table 7, hydrogels of Compounds A, B, C and D were prepared, which consisted of a certain amount of the active ingredients, as well as methylcellulose (2.5%), propylene glycol (11%), glycerol (11%), acetic acid (pH adjuster; 0 to 0.5 g). All excipients were obtained from Sinopharm Chemical Reagent Co. Ltd. The gel was made with water for injection.
[0404] Dexamethasone acetate cream (5 mg DEX in 10 g cream, Pharmaceutical Co. Ltd., Anhui, China) was used as a positive control.
[0405] 40 μL of each treatment drug was applied to the right ear of each group.
[0406] Table 7
[0407]
[0408] The results are Fig.13 The conjugates all have very good effects in eliminating edema caused by acute inflammation.
[0409] Example 10
[0410] Acute Wound Model II
[0411] Similar experiments were performed on 6 to 8 week old male C57BL / 6 mice using a protocol essentially identical to that described in Example 6 above.
[0412] Two circular wounds were made on the dorsal midline using an EMS skin biopsy punch with a diameter of 12 mm. The two circles were tangent to each other, and the skin between the circles was incised along the upper and lower tangent lines. The wounds were trimmed using scissors. The wounds were oval in shape.
[0413] Different drugs were topically administered at 50 μL / wound once a day from day 0 to day 7. The model group was given the same amount of normal saline. There were 10 groups in this experiment, including 80 mice, as shown in Table 8 below.
[0414] Table 8
[0415]
[0416] Photographs of each wound were taken every other day starting from day 0 and non-healed wound areas were represented as described in Example 6 above.
[0417] The rate of unhealed wounds Fig.14 The results show that all four conjugates (A, B, C and D) have comparable effects in promoting wound healing compared to the other groups.
[0418] Embodiment 11
[0419] Cream preparations
[0420] Sorbitol stearate (0.6 g), polysorbate-80 (1 g), cetyl alcohol (2 g), caprylic / capric glycerides (5 g), liquid paraffin (4 g), glyceryl monostearate (2 g) and petrolatum (5 g) (all from Sinopharm Chemical Reagent Co. Ltd.) were mixed together while stirring and heating to 85° C. until the mixture was completely melted.
[0421] Methylcellulose (0.5 g), glycerol (4 g), trehalose (0.5 g), polyethylene glycol 200 (4 g), phenoxyethanol (0.3 g) and ethylhexylglycerol (0.1 g) (all from Sinopharm Chemical Reagent Co. Ltd.) were mixed with purified water (69.45 g) while stirring and heating to 85° C. to give a uniform colloidal suspension.
[0422] The two mixtures obtained above were mixed together with silicone oil (0.5 g) for 5 minutes under rapid stirring using an emulsifying apparatus. The resulting emulsion was cooled to 55°C.
[0423] Compound A (50 mg; see Example 1 above) was dissolved in purified water (1 g) and then combined with the emulsion mixture under stirring until it was homogeneous. The resulting mixture was allowed to cool to room temperature to obtain the finished product.
[0424] Example 12
[0425] Spray Formulations I
[0426] Hydroxypropyl methylcellulose (HPMC; 0.1 g), hydroxyethyl cellulose (0.1 g), glucose (5 g), phenoxy alcohol (0.5 g) (all from Sinopharm Chemical Reagent Co., Ltd.) and purified water (93.25 g) were stirred together while heating to 85° C. to provide a uniform colloidal suspension. The mixture was then cooled to room temperature.
[0427] Compound A (50 mg; see Example 1 above) was dissolved in 1 g of purified water. This solution was added to the colloidal mixture. Mixing was performed uniformly to give the finished product.
[0428] Example 13
[0429] Spray Preparation II
[0430] A second spray was prepared using essentially the same procedure as described above in Example 12 by adding the same aqueous solution of Compound A to a colloid mixture made with slightly more HPMC and hydroxyethylcellulose (0.2 g each) and the same amounts of other components and 94.05 g of purified water.
[0431] Embodiment 14
[0432] Gel Formulation I
[0433] This formulation was obtained using essentially the same procedure as described in Examples 12 and 13 above by adding the same aqueous solution of Compound A to a colloidal mixture made of 1 g each of HPMC and hydroxyethylcellulose and the same amounts of other components and 91.45 g of purified water.
[0434] Embodiment 15
[0435] Gel Formulation II
[0436] A second gel was obtained using essentially the same procedure as described in Examples 12 to 14 above by adding the same aqueous solution of Compound A to a colloid mixture made of 0.5 g HPMC and 1.5 g hydroxyethylcellulose and the same amounts of other components and 91.45 g purified water.
[0437] Example 16
[0438] Gel Formulation III
[0439] The third gel was obtained using substantially the same procedure as described in Examples 12 to 15 above. Methylcellulose (2.2 g) and 11 g of propylene glycol (all from Sinopharm Chemical Reagent Co., Ltd.) and glycerol (11 g) were first mixed with 74.75 g of purified water. The same aqueous solution of Compound A was added to the resulting colloidal mixture to provide a finished product.
[0440] Embodiment 17
[0441] Clinical Example I - Allergic Rhinitis Patients
[0442] A 45-year-old female patient with allergic rhinitis presented with periodic runny nose and nasal congestion.
[0443] Spray Formulation I (see Example 12 above) in a nasal spray bottle was administered individually to each nostril 2 to 3 times per day for 5 days.
[0444] The patient was instructed not to take her current medications (oral montelukast sodium and budesonide) starting with the first dose of the spray formulation.
[0445] Starting with the second dose, the runny nose and nasal congestion were significantly relieved. The patient found that she did not feel the need to take oral montelukast sodium during administration of the new formulation. Budesonide has been found to lose its efficacy within two months of use.
[0446] Embodiment 18
[0447] Clinical Example II - Symptom Relief in Burn Patients
[0448] A male patient presented with severe itching on the inner side of his upper arm while recovering from severe second degree burns with a VAS of 4 to 5.
[0449] Spray Formulation I (see Example 12 above) was administered to the wound and the itching was relieved within one minute.
[0450] Embodiment 19
[0451] Clinical Example III - Symptom Relief in Injured Patients
[0452] One patient underwent surgery and subsequently experienced severe pain from the surgical incision.
[0453] Spray Formulation I (see Example 12 above) was administered to the incision and pain was relieved within one minute.
[0454] Embodiment 20
[0455] Clinical Example IV - Allergic Rhinitis Patients
[0456] Thirty-eight subjects with seasonal and / or persistent allergic rhinitis participated in this study. Most subjects had had the disease for many years and had tried treatment with several medications including steroids. Subjects were instructed not to use their existing medications starting with the first dose of the spray formulation.
[0457] Spray Formulation I (see Example 12 above) in a nasal spray bottle was administered individually to each nostril twice daily for 7 days.
[0458] 4 subjects did not complete the study. Feedback information collected from the remaining 34 subjects is shown in Table 9 below.
[0459] The symptom incidence rate is equal to the number of subjects with a specific symptom divided by the total number of subjects. The effective rate is equal to the number of subjects whose symptoms are relieved divided by the total number of subjects with a specific symptom.
[0460] Table 9
[0461]
[0462] Patients found the spray formulation easy to administer and non-irritating. Nasal congestion was quickly relieved along with persistent sneezing and itchy eyes. After 7 days of using the spray, 16 subjects were examined by a clinician. 50% of the patients showed less turbinate swelling, 68.75% had less nasal secretions, and 43% showed reduced mucosal edema. No side effects were reported.
[0463] Embodiment 21
[0464] Clinical Example V - Relief of sore throat by nebulization inhalation
[0465] An 80-year-old Caucasian male has a sensation associated with the onset of the common cold. Symptoms include itchy throat and dull pain, and nasal congestion. 5mL of spray formulation I (see Example 12 above) is loaded into a portable sprayer (FeellifeMedical INC, Shenzhen, China). The nozzle of the sprayer is placed in the mouth and then the device is turned on. Continue to treat for about 10 minutes. Inhalation is only performed once. In the morning of the second day, all cold symptoms disappeared.
[0466] Embodiment 22
[0467] Clinical Example VI - Surgical Pain Relief in Burn Patients
[0468] A patient with large deep second degree burns covering his entire back was hospitalized at the burn department of Beijing Jishuitan Hospital. He was treated for severe burns and suffered what he described as unbearable surgical pain with a VAS of 7 to 9 at every change of his dressings.
[0469] The spray formulation I (see Example 12 above) in the spray bottle was sprayed directly onto the surface of the burn wound. After 5 minutes, the dressing was removed and a new dressing was put on. According to the evaluation of the clinician, the surgical pain was reduced by about two-thirds after the use of the spray.
[0470] Embodiment 23
[0471] Clinical Example VII - Surgical Pain Relief in Laser Surgery Patients
[0472] Two subjects were tested in this study. The subjects underwent surgical removal of skin pigmentation by fractional laser treatment.
[0473] Spray formulation I (see Example 12 above) in a spray bottle was sprayed onto the surface of the surgical area. After 10 minutes, laser surgery was started. According to the clinician's assessment, surgical pain was reduced by about one third after the use of the spray.
[0474] It is also normal for subjects undergoing this type of laser surgery to experience burning pain for about 30 minutes after the treatment. However, in this study, the subjects did not feel any burning pain afterwards.
[0475] Embodiment 24
[0476] Clinical Example VIII - Fever and Cough Relief
[0477] A 5-year-old boy caught a cold and developed a severe cough. His temperature reached 38°C during the night and he complained of a sore throat.
[0478] Spray Formulation I (see Example 12 above) in a spray bottle was administered as an oral spray 4 times a day. Symptoms of fever and sore throat disappeared on the second day. Cough disappeared after 3 days.
[0479] Embodiment 25
[0480] Clinical Example IX - Contact Dermatitis Relief
[0481] A 53-year-old woman presented with contact dermatitis on her neck. The rash and itching occurred when she wore a metal necklace.
[0482] Spray formulation I (see Example 12 above) in a spray bottle was sprayed onto the affected area. The itching sensation was relieved within 5 minutes. After taking 2 doses (one in the evening and one the next morning), all symptoms disappeared.
[0483] Embodiment 26
[0484] Clinical Example X - Cold Relief
[0485] The patients were a 42-year-old woman and her 10-year-old son. They both had a cold and suffered from sore throats and runny noses.
[0486] Spray Formulation I (see Example 12 above) in a spray bottle was administered as an oral spray. After taking 2 doses (one in the evening and one the next morning), all symptoms disappeared.
[0487] Embodiment 27
[0488] Clinical Example XI - Allergic Skin Disorders
[0489] A 27-year-old woman with sensitive skin had acneiform allergic skin disorder and mild itching on her face. She also had patches of redness and swelling on her face.
[0490] Spray formulation I (see Example 12 above) in a spray bottle was applied directly to the affected area of the face, 2 sprays at a time, 3 times a day. The itching sensation was relieved within 30 minutes. After two weeks, the lesions disappeared completely.
[0491] Embodiment 28
[0492] Animal Model I-Idiopathic Pulmonary Fibrosis (IPF)
[0493] Experimental animals and groups: After 7 days of adaptive feeding, 72 adult male Sprague Dawley rats were divided into 6 groups: sham operation (no infection and no treatment) group, IPF model group (no treatment), high drug dose test group, medium drug dose test group, low drug dose test group and positive control group.
[0494] The doses of compound A (Example 1) were set to 0.5 mg / mL, 0.1 mg / mL and 0.02 mg / mL as high dose, medium dose and low dose, respectively. Pirfenidone ( BeijingContinent Pharmaceutical Co., Ltd., Beijing, China) was used as a positive control drug.
[0495] Modeling and administration: A pulmonary fibrosis model was established by intratracheal instillation of bleomycin. Rats were anesthetized and placed on an operating table in a supine position to expose the trachea. Bleomycin (5 mg / kg) saline solution was injected into the trachea through the gap between the tracheal cartilage rings. An equal volume of normal saline was given to the sham group. After administration, the rats were quickly lifted vertically and rotated to evenly disperse the drugs. Once the rats recovered, after about 5 days, they were given different drugs for 28 consecutive days according to the model plan. The experimental plan is shown in Table 10 below.
[0496] Table 10
[0497] Group deal with dose Sham operation brine 50μl IPF model group brine 50μl Positive Control Pirfenidone 250mg / kg Compound A, high Compound A 975μg / rat Compound A, medium Compound A 195μg / rat Compound A, low Compound A 39μg / rat
[0498] Study the following observation indicators.
[0499] 1) The rats were observed daily for general activity, sensitivity to external stimuli, coat sheen, hair color, mouth, lips, nose, weight, diet, respiration, and mortality.
[0500] 2) The lung organ coefficient and lung wet / dry weight ratio (ie, the ratio of the lung organ weight of the animal to the body weight of the animal, ie, the ratio of internal organs to body weight) of the rats were determined.
[0501] 3) During the process of pulmonary fibrosis formation, the expression of growth factor (TGF-β), tumor necrosis factor-α (TNF-α) and other cytokines related to the onset of fibrosis were measured. The content of TGF-β, TNF-α, IL-1β, malondialdehyde (MDA) and the activity of superoxide dismutase (SOD) in lung tissue were detected using standard ELISA method.
[0502] 4) Detect the content of collagen and fibrin metabolites (hydroxyproline) in the lungs as a specific indicator for assessing the degree of pulmonary fibrosis.
[0503] 5) Detecting the histopathological changes of lung tissue, which is the most important and objective indicator for evaluating pulmonary fibrosis.
[0504] The results showed that compound A inhibited the overproduction of TGF-β and inflammatory cytokines. The results also showed that the tested drug had an antioxidant effect by increasing SOD production and reducing lipid oxidation.
[0505] Embodiment 29
[0506] Animal model II-antitussive experiment: ammonia-induced cough method in mice.
[0507] 60 mice were randomly divided into 5 groups according to their body weight: CMC-Na negative control group, dextromethorphan hydrobromide positive control group, and high-dose, medium-dose and low-dose (Compound A, Example 1) groups. Each group contained 12 mice, 6 males and 6 females.
[0508] The test drug was administered by nebulization inhalation (0.15 mL / min) for 1 min once a day for 5 days. The positive control drug was administered intragastrically at 10 mg / kg once a day for 5 days.
[0509] 1, 2 and 4 hours after the last drug administration (Compound A or positive control drug), mice were placed in an inverted beaker. 1mL of ammonia (25.0% to 28.0%) was placed on top of a boiling water bath and evaporated into a beaker. Mice were stimulated by ammonia vapor for a predetermined time of 63.1, 50.1, 39.8, 31.6, 25.1, 20.0, 15.9 or 12.6 seconds. The difference of the logarithm of two adjacent stimulation times was set to 0.1, and was 1.8, 1.7, 1.6, 1.5, 1.4, 1.3, 1.2 and 1.1 respectively. The mice were then quickly moved to a bell jar. The number of coughs in 1 minute was detected with a stethoscope. Three or more typical coughs in one minute were called 'cough', and less than three typical coughs in one minute were called 'no cough'.
[0510] The ammonia stimulation time for the next mouse was determined according to the principle of the sequential method, i.e., if the first mouse 'coughed', the next mouse was stimulated for a shorter period of time. Conversely, if the first mouse 'did not cough', the next mouse was stimulated for a longer period of time.
[0511] EDT 50 The ammonia stimulation time was defined as the time at which half of the mice developed a "cough" and was calculated by the following equation:
[0512] EDT 50 =lg -1 c / n
[0513] (c equals the sum of r and x, r is the number of animals in each stimulation time group, x is the logarithm of the stimulation time, and n is the number of animals in each group.) The results are shown in Table 11 below.
[0514] Table 11
[0515]
[0516]
[0517] Where R1 = (EDT of the treatment group 50 / EDT in the control group 50 )×100%, R>130% indicates an antitussive effect. R>150% indicates a strong antitussive effect.
[0518] The results showed that compound A had a positive effect on cough relief.
[0519] Embodiment 30
[0520] Animal Model III-Expectorant Experiment-Phenol Red Excretion Method in Mice.
[0521] Fifty mice were randomly divided into five groups according to body weight: saline negative control group, ammonium chloride positive control group, and high, medium and low doses of the test drug (Compound A above or Compound E below). Each group had 10 mice, 5 males and 5 females.
[0522] Compound A was administered by nebulization inhalation (0.15 mL / min) for 1 min once a day for 5 days, and a positive control drug was administered by intragastrically for 5 days.
[0523] Half an hour after the last administration of compound A, 5% phenol red solution was injected into the abdominal cavity. Mice were killed after another half an hour. The neck skin was removed, and the trachea from the thyroid cartilage to the bifurcation was isolated and immersed in 5% sodium bicarbonate solution while shaking continuously. The phenol red content was detected using sodium bicarbonate solution.
[0524] The absorbance at 558 nm was detected by spectrophotometry (721G spectrophotometer, Shanghai Jingke, Shanghai, China). The phenol red content in the trachea was calculated using the optical density value by referring to the phenol red standard curve. The results of each group and the negative control group were tested by a significant t test. The results of the expectorant experiment are shown in Table 12 below.
[0525] Table 12
[0526] Group deal with dose Phenol red concentration (μg / ml) Negative control Normal saline 6.970±0.339 Positive Control <![CDATA[NH4Cl]]> 0.15g / kg <![CDATA[10.335±0.337 ** ]]> high Compound A 39μg / mouse 9.001±0.637 medium Compound A 195μg / mouse <![CDATA[10.480±0.550 *** ]]> Low Compound A 975μg / mouse <![CDATA[10.489±0.610 *** ]]>
[0527] Compared with negative control: *P<0.05, **P<0.01, ***P<0.001
[0528] The results showed that Compound A reduced mucus production and therefore reduced sputum.
[0529] Embodiment 31
[0530] Effect of Compound A on the Activity of Human Herpes Simplex Virus Type II (HSV-II)
[0531] Serum-free 1640 medium was prepared using RPMI1640 powder (1000 mL dose; Thermo Fisher Scientific China), L-glutamine (0.29 g; Sinopharm Chemical Reagent Co. Ltd, Shanghai, China), sodium bicarbonate (2.2 g; Sinopharm Chemical Reagent Co.), HEPE (2.39 g; Thermo Fisher Scientific China), and deionized water (1000 mL).
[0532] The reagents were mixed until they dissolved, and the solution was then sterilized by filtration. The mixture was made up to complete medium containing 10% serum by adding 10% newborn calf serum, or to maintenance solution by adding 2% newborn calf serum before use.
[0533] 20 mg of compound A (Example 1) was dissolved in 1 ml of 0.9% sodium chloride aqueous solution to prepare a 20 μg / μL stock solution. 0.05 mL of the stock solution was added to 1.95 mL of complete (10%) culture medium to prepare a 500 μg / mL drug solution. In the following antiviral tests No. 3 and No. 4, maintenance solution (2%) was used instead of complete culture medium.
[0534] Working solutions at concentrations of 250 μg / mL, 125, 62.5 μg / mL, 31.25 μg / mL, 15.625 μg / mL, 7.8125 μg / mL, 3.9063 μg / mL, 1.9531 μg / mL, and 0.9766 μg / mL were prepared by double dilution.
[0535] 20.34 mg of sodium lauryl sulfate (SDS; manufactured by AMRESCO LLC, Solon, Ohio, USA and packaged by Biosharp Company, Hefei, China; purity: 99%) was dissolved in 10.17 mL of complete medium to produce a 2000 μg / mL stock solution. A similar stock solution was also prepared in the same manner using the maintenance solution for antiviral testing. A working solution with the concentrations described above was then prepared by double dilution.
[0536] 2.25 mg of acyclovir (ACV; Zhiyuan Pharmaceutical Co., Ltd, Wuxi, China; purity: 99.3%) was dissolved in 2.25 mL of complete medium to form a stock solution of 1000 g / mL. Similar stock solutions were also prepared in the same manner using the maintenance solution for antiviral testing. 0.8 mL of each stock solution was double diluted to provide working solutions with concentrations of 500 μg / mL, 250 μg / mL, and 125 μg / mL. 0.2 mL of each stock solution was added to 1.95 mL of complete medium to provide a concentration of 100 μg / mL, which was then diluted to provide solutions with concentrations of 50 μg / mL, 25 μg / mL, and 12.5 μg / mL.
[0537] 1. HSV-2 Virus Toxicity Test
[0538] 0.5 mL of a suspension of human herpes simplex virus type II (HSV-2; SAV strain; Shanghai Institute of Cell Biology) was inoculated into a monolayer culture of Vero cells (Shanghai Institute of Cell Biology), and the virus suspension was removed after 1 hour of adsorption.
[0539] Maintenance solution was added and cultured at 37°C under 5% CO2 until more than 95% of the cells showed obvious pathological changes under a microscope (Nikon ECLIPSE TS100 inverted phase control microscope with imaging system). The cells were harvested, repeatedly frozen and thawed (3 cycles), and then centrifuged at 3000 rpm for 10 minutes in a 400C medical low-speed centrifuge (Beijing Baiyang Centrifuge Co., Ltd.). The supernatant was collected as a virus solution.
[0540] The density is 2×10 5Vero cell suspension of (cell number) was inoculated into 96-well culture plates (Costar, Corning Inc., Oneonta, New York, USA) at 0.1 mL / well and cultured at 37°C for 18 hours in a Thermo Scientific CO2 incubator at 5% CO2 until a single layer was visible under a microscope. The viruses collected above were inoculated into single-layer Vero cells diluted 10 times in maintenance solution at 0.1 mL / well each. Maintenance solution was supplemented and cultured at 37°C at 5% CO2. After 24 hours of culture, pathological changes of cells were observed under a microscope. Each dilution was repeated in 3 wells. Normal cells were used as experimental controls. Virus toxicity tests were repeated 3 times.
[0541] Three fields of view were observed in each well, and the average percentage of pathological cells (P) in the field of view was determined.
[0542] The TCID50 of the virus was calculated according to the conventional method of Reed and Muench. 50 , 50% tissue culture infectious dose of the virus), i.e. TCID 50 , which is the logarithm of the dilution that shows a mortality rate just above 50% - (logarithmic difference x logarithm of the dilution factor). Typically, the "logarithmic difference" (logarithmic difference is also called "proportional distance" or "interpolated value") is calculated using the following formula: logarithmic difference = [(mortality rate at the dilution just above 50%) - 50%] / [(mortality rate just above 50%) - (mortality rate just below 50%)].
[0543] 2. Cytotoxicity of Compound A and Control Drugs
[0544] Vero cells were seeded on 96-well culture plates and grown into a monolayer. 0.2 mL of Compound A solution (Example 1) or control drug (20.34 mg sodium lauryl sulfate or 2.25 mg acyclovir, as described above) was added to each well, each well containing different concentrations of complete medium (as described above). For each concentration, it was repeated in 3 wells.
[0545] Solvent and normal cell culture were used as negative controls. Cells were cultured at 37°C under 5% CO2 and the growth and morphological changes of cells were observed under a microscope for 2 days. For each well, three fields of view were selected under a microscope, the percentage of pathological cells was counted, and the average value was calculated. The evaluation time point of the test was set to 24 hours, and the half toxic concentration (TC 50 ) and maximum non-toxic concentration (TC0). The experiment was repeated 3 times.
[0546] Cells were inoculated as described above. Solvent and normal cell culture were used as negative controls. 24 hours after adding compound A or control drug, 5 mg / mL of 3- (4,5-dimethyl-2-thiazolyl) -2,5-diphenyl-2-H- tetrazolium bromide (MTT, Sigma-Aldrich (China), Shanghai, China) (diluted from 10x stock solution, Sigma-Aldrich (China)) (20 μL / hole) in PBS was introduced, and culture was continued for 4 hours. The supernatant in each well was then discarded and 150 μL dimethyl sulfoxide (DMSO) was added; Sigma-Aldrich (China)), then shaken in the dark at room temperature for 10 minutes.
[0547] The optical absorption value (OD) at 550 nm was measured by enzyme-linked immunosorbent assay (Multiskan Spectrum; Thermo Scientific, Shanghai, China). 550 ).
[0548] 3. Test the effect of drugs and SDS on the cytopathic effect of the virus after direct action on HSV-2
[0549] The TCID-positive 50 The HSV-2 virus was diluted to a titer of 200 TCID 50 (Each time TCID is initially determined 50 value, allowing determination of 200TCID 50 ). 200TCID 50 The solution and the virus titer of equal volume are 100TCID 50 The mixed solution was incubated in a water bath (DK-8B constant temperature electric water bath; Shanghai Jinghong Biotech Co., Ltd.) at 37°C for 1 hour, and then seeded in a 96-well culture plate containing a monolayer of Vero cells. 0.1 mL of the mixed solution was added to each well.
[0550] After 1 hour of adsorption, the supernatant containing virus and drug was discarded. The monolayer Vero cells were then washed twice with maintenance solution. Finally, 0.2 mL of maintenance solution was added to each well. The resulting mixture was continuously cultured at 37°C under 5% CO2 until the cytopathic rate of the drug-free culture reached 95% under a microscope. The evaluation time point of the test was set to 24 hours.
[0551] In addition to the experimental groups, three control groups were tested in parallel: solvent, no drug control (virus control) and normal cell control. Each group consisted of 3 wells and the experiment was repeated 4 times.
[0552] The virus culture was diluted to 0.1, 1, 10, 100, and 1000 TCID 50 , and then inoculated into monolayer cell culture. Each dilution was performed in triplicate. The cytopathic rate of each well was observed. 50 There should be no cytopathic effect at 100 TCID 50 A cytopathic effect should be seen; otherwise the neutralization test is not established.
[0553] The evaluation index is the same as that in the virus toxicity test. For each well, three fields of view were observed under a microscope. The average percentage of pathological cells (P) in the field of view was determined and the half infectious dose (TCID) of the virus was calculated according to the Reed and Muencl method (as described above). 50 ).
[0554] The drug toxicity to Vero cells was determined by cell morphology, and antiviral tests were performed at non-toxic concentrations. After incubation with different concentrations of test drugs and SDS for 1 hour, 100 TCID 50 HSV-2 (SAV strain) was inoculated into monolayer Vero cell cultures.
[0555] The results showed that the cytopathic effect of cells caused by viral infection was inhibited to varying degrees, indicating that compound A has an inhibitory effect on the virus HSV-2.
[0556] 4. Testing the effects of drugs and ACV on HSV-2 (direct method)
[0557] Dilute the virus to 100 TCID 50 And inoculated into the monolayer Vero cell culture at 0.1mL in each well. After adsorption for 1 hour, the supernatant was discarded and the culture was washed twice with maintenance solution. Then, solutions with different concentrations of compound A or control drug (acyclovir) were added at 0.2mL / well. The culture was continuously cultured at 37°C under 5% CO2. Each concentration was repeated in triplicate.
[0558] In addition to the experimental groups, three control groups were tested in parallel: solvent, no-drug control (virus control), and normal cell control.
[0559] During the culture period, pathological changes were observed under a microscope, and the test was terminated when the cytopathic rate of the virus control reached >95%. The evaluation time point of the test was 24 hours and the experiment was repeated 3 times.
[0560] The judgment criteria were the same as those used in the virus toxicity test, that is, three fields were selected for microscopic examination of each well, the average percentage of pathological cells (P) in the field was determined, and the average of the three fields was taken.
[0561] A linear regression equation was calculated based on the percentage of cytopathic effect versus drug concentration for each reagent concentration group. 50 The significance test of the correlation coefficient is also calculated.
[0562] The results showed that compound A had antiviral effect.
[0563] Embodiment 32
[0564] Montelukast-Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Lys (i.e., with an amino group at the N-terminus Synthesis of montelukast covalently bonded to 1,2-dihydro-1,4 ...
[0565] The procedure was repeated as described in Example 1. The second product peak was detected at 5.813 by LCMS (Analytical column model: GS-120-5-C18-BIO, 4.6*250 mm; Detection: UV at 220 nm; Solvent A: 0.1% TFA in MeCN, Solvent A: 0.1% TFA in water; Flow rate: 1.0 mL / min; Volume: 10 μL).
[0566] MS: m / z 875.90[M+2H] 2+ .
[0567] Based on the characterization data available and presented herein, it is understood that the compound isolated by this example is the compound identified above as the title compound. The compound of Example 32 is hereinafter referred to as "Compound E".
[0568] The yield ratio of compound E to compound A is 1:9.
[0569] Embodiment 33
[0570] Hydrogenated montelukast styrene-Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Lys (i.e., at the N-terminus Synthesis of hydrogenated montelukast styrene covalently bonded to the amino acid SEQ ID No: 12 at the end
[0571] The synthesis of the above compound was exactly the same procedure as described in Example 1 for Compound A, except that montelukast styrene was used instead of montelukast as reagent.
[0572] MS: m / z 867.91[M+2H] 2+ .
[0573] Based on the characterization data available and presented herein, it is understood that the compound prepared by this example is the compound identified above as the title compound. In addition, the compound prepared in Example 33 is a compound of the present invention, wherein in the compound of Formula I, and n is 0 and the compound of Formula I is covalently bonded to the amino acid SEQ ID No: 12 at the N-terminus. In any case, the compound of Example 33 is hereinafter referred to as "Compound F".
[0574] Embodiment 34
[0575] Clinical Example XII - Fever Relief
[0576] An 11-year-old boy presented with fever with a temperature of 39° C. at 2100 hours. The subject also coughed intermittently and had a runny nose.
[0577] At 2200 hours, a spray formulation of Compound E (2 mg; see Example 32 above) in normal saline (5 mL) was administered as a mist to each nostril by nebulization (device: handheld nebulizer, Lifetrons Beaute NS-400) over a 5 minute period.
[0578] At 2215 hours, the subject fell asleep. Around midnight, the subject began to sweat and his temperature dropped slightly. At 0030 hours, a second dose of Compound E (1 mg) in physiological saline solution (2.5 mL) was administered in the same manner.
[0579] By 0330 hours, the subject's temperature had dropped to 37.0°C. By 0800 hours, the subject had a normal temperature. Thus, a total of only one cough was observed per half minute between 2215 hours the previous day and 0800 hours the next day. During sleep that night, there was no observable nasal obstruction. In the morning, although the runny nose reappeared, it was significantly improved compared to the previous 11 hours.
[0580] At 0830 hours on the same morning, the subject received a third dose of Compound E (1 mg) in normal saline (2.5 mL), which was administered in the same manner. Two hours later, his nose had stopped running. Thereafter and until 1500 hours on the same day, the subject had no fever, cough or runny nose.
[0581] At 1530 o'clock on the second day, the subject received a fourth dose of Compound E (1 mg) in a saline solution (10 mL) by nebulization (equipment: Yuyue, air compression nebulizer, 403M). At 2045 o'clock, the subject had a temperature of 37.1°C. At 2100 o'clock, the subject received a fifth dose of Compound E (1 mg) in a saline solution (10 mL) by nebulization. By 2215 o'clock, the subject's temperature was 36.8°C.
[0582] Embodiment 35
[0583] Comparison of Compounds A and E in the Mouse Ear Swelling Model (III)
[0584] A similar experiment was performed on 30 healthy male BALB / c mice using a protocol essentially identical to that described above in Example 5. The mice were randomly divided into 6 groups, as described in Table 13 below, with 5 mice in each group.
[0585] Table 13
[0586]
[0587] Compounds A and E were obtained from GL Biochem Ltd and synthesized as described in Examples 1 and 32, respectively. Aqueous solutions of Compounds A and E were prepared by dissolving 0.5 mg powder in 1 mL saline (0.9% w / v NaCl solution). 40 μL of the prepared solution was applied to the right ear of each group.
[0588] Dexamethasone acetate cream (5 mg DEX in 10 g cream, Fuyuan Pharmaceutical Co. Ltd., Anhui, China), budesonide nasal spray (32 μg / spray × 120 sprays, 0.64 mg / ml, AstraZeneca AB, SE-151 85, Sodertal, Sweden) were used. ) and fluticasone propionate nasal spray (50mcg / spray, 0.05% w / w, Glaxo Wellcome, SA, Calle Extremadura n°3-09400, Aranda de Duero, Burgos, Spain) as positive controls. The cream was placed in a 1 mL syringe to measure the dose based on a weight and volume calibration. The spray bottle was opened and 40 μL of liquid was drawn up with a pipette and applied to the right ear of each group.
[0589] The results are Fig.15 Shown in.
[0590] The conjugates all have very good effects in eliminating edema caused by acute inflammation. The anti-inflammatory effects of compounds A and E are equivalent.
[0591] Embodiment 36
[0592] Montelukast-Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-Hyp-Lys (i.e., with an amino group at the N-terminus Montelukast covalently bonded to the acid SEQ ID No: 22) and Montelukast styrene-Ala-Lys-Pro-Ser-Tyr-Hyp- Thr-Tyr-Hyp-Lys (i.e., montelukast styrene covalently bonded to the amino acid SEQ ID No: 22 at the N-terminus) synthesis
[0593] A modified peptide having SEQ ID No: 22 was synthesized using essentially the same procedure as described in Example 1 above, but wherein the order of the coupling steps was adjusted to provide in accordance with the amino acid sequence above.
[0594] Thereafter, montelukast was coupled to the N-terminus of Ala. The two title compounds were isolated and thereby purified by LCMS in a manner similar to that described above in Example 32. The compounds are hereinafter referred to as Compound G (comprising montelukast) and Compound H (comprising montelukast styrene), respectively.
[0595] The yield ratio of compound G:H is 1:7
[0596] MS (Compound G): m / z 876.6 [M+2H]2 +
[0597] MS (Compound H): m / z 867.6 [M+2H]2 +
[0598] Embodiment 37
[0599] In vitro CysLTR1 FLIPR antagonism assay
[0600] Using Fluo-4 Direct TM The calcium assay kit [Cat. No. F10471, Thermo Fisher Scientific] measured the in vitro antagonistic effects of Compounds A and E (see Examples 1 and 32 above, respectively) on CYSLTR1 cell lines. As a comparison, montelukast sodium and montelukast styrene were also tested and pranlukast was used as a positive control. For each compound, 10 different concentrations were tested in duplicate.
[0601] CYSLTR1 / HEK293 cell line was used. Cells were prepared and 20 μL of cell suspension was added to a 384-well plate (20K / well; poly-D-lysine protein coated plate, Greiner #781946). The plate was placed in a 5% CO2 incubator at 37°C overnight.
[0602] Prepare probenecid in FLIPR assay buffer from the relevant starter pack (Cat. No. F10471) by adding 1 mL of Fluo-4 Direct TM Prepare a 250 mM aqueous probenecid stock solution in calcium assay buffer. Add 10 mL of Fluo-4 Direct TM Add calcium assay buffer and 200 μL of 250 mM probenecid stock solution to a bottle of Fluo-4 Direct TM Calcium reagent (Component A). This 2xFluo-4 Direct TM The calcium reagent loading solution is sufficient for two microplates. Allow the solution to sit for 5 minutes (protected from light) by vortexing to ensure complete dissolution of the reagent. The reagent is prepared fresh daily.
[0603] All compounds were dissolved and serially diluted in Fluo-4 Direct TM Calcium Assay Buffer (without probenecid). Remove the cell plate from the incubator and gently decant the medium. Transfer 20 μL of compound to the cell plate and add 20 μL of 2x Fluo-4 Direct TM No wash loading buffer. The final concentration of each compound was 100 μM, 30 μM, 10 μM, 3 μM, 1 μM, 0.3 μM, 0.1 μM and 0.03 μM. The plate was incubated at 37 ° C for 50 minutes in a 5% CO2 incubator and at room temperature for 10 minutes. Fluorescence was measured using instrument settings suitable for excitation at 494 nm and emission at 516 nm.
[0604] The data were analyzed using Prism (GraphPad Software, USA) and the IC50 of each compound was calculated. The results are shown in Table 14 below.
[0605] Table 14
[0606]
[0607] The results showed that the affinity of montelukast for CysLTR1 was 11 times that of montelukast styrene. Therefore, the affinity of compound E was 5 times higher than that of compound A, and the affinity of the tested compounds for CysLTR1 was largely dependent on the structure of the compound of formula I.
[0608] Embodiment 38
[0609] In vitro CysLTR1FLIPR antagonism assay
[0610] The assay procedure described in Example 37 above was repeated for Compound G (see Example 36 above), and further performed for Compound E (see Example 32 above) as a comparison. The results are shown in Table 15.
[0611] Table 15
[0612]
[0613] The results showed that compounds G and H had the same level of affinity for CysLTR1, indicating that changes in the amino acid sequence of the peptide had little effect on the affinity of the conjugate.
[0614] Embodiment 38
[0615] Lung injury induced by lipopolysaccharide in mice
[0616] Thirty-six BALB / c male mice weighing between 20 and 22 g were housed in an animal facility at between 22°C and 26°C and relative humidity between 55% and 75% and a 12 / 12 hour day / night cycle with ad libitum access to food and water.
[0617] The mice were randomly divided into 6 groups as indicated in Table 16 below.
[0618] Table 16
[0619] Group dose give Comparison / / Model brine Inhalation Compound A 2mg / kg Inhalation Compound G (high dose) 10mg / kg Inhalation Compound G (medium dose) 2mg / kg Inhalation Compound G (low dose) 0.4mg / kg Inhalation
[0620] Compound A was prepared similarly to the procedure described in Example 1 above, and Compound G was prepared similarly to the procedure described in Example 36 above.
[0621] Mice were anesthetized by intraperitoneal injection of 3% chloral hydrate (0.1 mL / 10 g). The tongue was pulled aside with forceps. Lipopolysaccharide (LPS, 1 mg / mL, 50 μL) was administered by pipetting to the posterior wall of the pharynx. The tongue was released and the nose was immediately pinched for 30 seconds. The detained mice were then released and returned to the cage to wake up naturally. The mice in the control group were treated with the same volume of normal saline.
[0622] After LPS induction, test compounds were administered via nebulization / inhalation 30 minutes later. 24 hours later, mice were sacrificed.
[0623] The chest cavity was opened quickly and the whole lung was removed. The lung tissue fragments were accurately weighed, and saline was added at a ratio of 9 mL saline to 1 g lung tissue. Then, the tissue was homogenized and centrifuged at 3000 rpm for 10 minutes. The homogenate was used to detect TGF-β1 using an ELISA kit (Beijing 4ABiotech Co., Ltd, China), and the results were Fig.16 Shown in.
[0624] The results showed that both compounds of the present invention reduced inflammatory cytokines in lung tissue. The IL-1β concentration level in lung tissue of the compound A group was the same as that of the low-dose compound G group. Compound G also showed a dose-dependent efficacy in reducing inflammatory cytokines.
[0625] Thus, although both compounds of the present invention have been shown to be effective in treating LPS-induced acute lung injury in mice, Compound G is approximately 5 times more potent than Compound A.
[0626] Embodiment 39
[0627] Rat idiopathic pulmonary fibrosis (IPF) model
[0628] 60 adult SD rats (30 males, 30 females) were purchased from Zhejiang Experimental Animal Center, China. The animals were housed between 21°C and 26°C and at a relative humidity between 40% and 70% with free access to food and water.
[0629] After 7 days of adaptive feeding, the rats were randomly divided into 6 groups as shown in Table 17 below.
[0630] Table 17
[0631] Group drug dose Giving Method Sham operation / / Inhalation Model Normal saline 0.15mL Inhalation Pirfenidone Pirfenidone 240mg / kg Tube feeding Compound A Compound A 2mg / kg Inhalation Compound E Compound E 2mg / kg Inhalation Compound H Compound H 2mg / kg Inhalation
[0632] The rats were anesthetized and placed on an operating table in a supine position to expose the trachea. Bleomycin (5 mg / kg, Bleomycin hydrochloride for injection, Haizheng Pfizer Pharmaceutical Co., Ltd.) and saline solution were injected into the trachea through the gaps between the tracheal cartilage rings.
[0633] The sham group was given an equal volume of saline instead of bleomycin. Immediately after administration, the rats were lifted vertically and rotated to allow for uniform distribution of bleomycin.
[0634] Once the rats recovered, after about 7 days, they were given different drugs according to the model plan. 6.5 mg of the test compound of the present invention in powder form was accurately dissolved in 5 mL of saline to make a 1.3 mg / mL solution. 0.15 mL of the solution was atomized and inhaled by each rat. Inhalation was performed once a day.
[0635] For the pirfenidone group, 12 pirfenidone capsules (Beijing Contini Pharmaceutical Co., Ltd., Beijing, China; 100 mg) were opened and the contents were completely suspended in 25 mL of 0.5% CMC-Na solution to obtain a 48 mg / mL suspension. The dose of pirfenidone was 1.0 mL / 200 g in rats, i.e., 240 mg / kg, and was administered by oral gavage.
[0636] After 28 days of administration, the rats were anesthetized by intraperitoneal injection of chloral hydrate and then sacrificed. The chest cavity was quickly opened and the whole lung tissue was taken out. The lung wet weight was weighed, and the lung coefficient (lung wet weight / rat weight×1000) was calculated and shown in Table 18 below.
[0637] Table 18
[0638] Group Lung coefficient (%) Sham operation 6.272±0.496 Model 13.484±1.395 Compound A 8.771±0.897 Compound E 9.462±1.123 Compound H 9.825±0.647 Pirfenidone 10.218±0.984
[0639] The results showed that compounds A, E and H reduced the pulmonary edema induced by bleomycin.
[0640] The right bronchus was ligated and the left lung was perfused with formalin solution in vitro. The left lung was cut open and fixed in formalin solution for pathological examination. The remaining tissue was stored in a -80°C refrigerator for later use.
[0641] The fixed lung tissue was embedded in paraffin, and continuous 4 μm sections were stained with hematoxylin-eosin (HE) and modified Masson trichrome staining. Fibrotic lung injury was evaluated morphologically by semiquantitative parameters. All morphological changes were scored according to the severity of the damage. Score was given, with 1-4 points for mild, low, moderate and severe. No lesion score was 0. The assessment of HE stained sections was the sum of the degree of fibrosis and the degree of inflammation. The assessment of Masson stained sections was the degree of collagen deposition in the pulmonary interstitium. The results are shown in Table 19 below.
[0642] Table 19
[0643]
[0644] The results showed that compared with the sham operation group, the pulmonary fibrosis and bronchopneumonia in the model group were more severe. Compared with the model group, the pathological changes in the drug-treated group were similar, and the degree of pathological changes was smaller. The order of pathological changes was as follows: model, pirfenidone>compound E>compound A>compound H>sham operation. These results indicate that compounds A, E and H prevent bleomycin-induced mouse pulmonary fibrosis, and their efficacy is stronger than that of pirfenidone.
[0645] Embodiment 40
[0646] Montelukast-Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Hyp-Lys (i.e., at the N-terminus Synthesis of montelukast (styrene) covalently bonded to the amino acid SEQ ID No: 20
[0647] A modified peptide having SEQ ID No: 20 was synthesized using essentially the same procedure as described in Example 1 above, but wherein the order of the coupling steps was adjusted to provide in accordance with the amino acid sequence above.
[0648] Thereafter, montelukast was coupled to the N-terminus of Ala. The compound was purified by LCMS in a manner similar to that described above in Example 32. The title compound is hereinafter referred to as Compound J.
[0649] MS: m / z 924.15[M+2H]2+
[0650] Embodiment 41
[0651] Mouse ear swelling model IV
[0652] Using Compound J (see Example 40 above) as the test compound, 15 healthy male BALB / c mice were subjected to a protocol essentially identical to that described above in Example 5. The mice were randomly divided into 3 groups, as described in Table 20 below, with 5 mice in each group.
[0653] A hydrogel of Compound J was prepared containing 0.5 mg / g of active ingredient and methylcellulose (2.5%), propylene glycol (11%), glycerol (11%), acetic acid (pH adjuster; 0 to 0.5 g). All excipients were obtained from Sinopharm Chemical Reagent Co. Ltd. The gel was made with water for injection.
[0654] Dexamethasone acetate cream (DEX cream; 5 mg dexamethasone in 10 g cream; Fuyuan Pharmaceutical Co. Ltd., Anhui, China) was used as a positive control. 40 μL of each treatment drug was applied to the right ear of each group.
[0655] Table 20
[0656]
[0657]
[0658] The results are Fig.17 Compound J showed a very good effect in eliminating edema caused by acute inflammation.
[0659] Embodiment 42
[0660] Clinical Example - Allergic Conjunctivitis
[0661] A 52-year-old female patient was diagnosed with allergic conjunctivitis and experienced eyelid swelling, itching, and rhinorrhea.
[0662] 0.5 mg / mL of Compound G in saline solution was placed in a spray bottle. The spray was administered to each eye 2 to 3 times a day for 7 days.
[0663] After one treatment, the patient felt relief from eye itching. On the second day of treatment, her eyelid swelling was less. All symptoms fully recovered within a week.
[0664] Embodiment 43
[0665] Clinical Example - Ulcerative Colitis
[0666] Hospitalized patients with ulcerative colitis suffer severe symptoms, including severe abdominal pain and cramping, frequent diarrhea (more than 20 times a day), and no response to over-the-counter medications. Patients experience rectal bleeding, small amounts of blood in the stool, urgency to defecate, and fever.
[0667] A hydrogel of Compound G was prepared, which consisted of 0.5 mg / g of active ingredient, methylcellulose (2.5%), propylene glycol (11%), glycerol (11%), acetic acid (pH adjuster; 0 to 0.5 g). All excipients were obtained from Sinopharm Chemical Reagent Co. Ltd. The gel was made with water for injection.
[0668] The patient was given 2 g of the above gel, administered anally, once a day. On the second day after administration, diarrhea decreased to only 5-6 times a day, with less bleeding.
[0669] To determine long-term efficacy, patients continued to use the gel.
[0670] The present invention also relates to the following embodiments:
[0671] Item 1. A peptide-containing compound comprising a peptide component, wherein the peptide component is a peptide having from 2 to 45 amino acids in number.
[0672] The peptide component is covalently bonded to one or more compounds of formula I:
[0673]
[0674] in:
[0675] R 1 is selected from -C(CH3)2OH, -COCH3, -C(CH3)=CH2 and -C(CH3)2H; and
[0676] n is 0, 1, or 2,
[0677] and the regioisomers, stereoisomers, and pharmaceutically or cosmetically acceptable salts of the peptide-containing compounds.
[0678] Item 2. The peptide-containing compound according to Item 1, wherein the peptide component comprises a sequence of 6 to 12 amino acids. Item 3. The peptide-containing compound according to Item 1 or Item 2, wherein the peptide component is
[0679] The primary amide bond formed at the N-terminus is coupled to at least one compound of formula I.
[0680] Item 4. A peptide-containing compound according to any one of the preceding items, wherein the peptide component is bonded via a primary amide bond.
[0681] is coupled to at least one compound of formula I, wherein the primary amide bond is formed by a
[0682] The N-terminal amino acid is formed by at least one free -NH2 group in one or more amino acids.
[0683] Item 5. A peptide-containing compound according to any one of the preceding items, wherein at least one of the peptide components
[0684] The amino acids are selected from lysine and / or arginine.
[0685] Item 6. The peptide-containing compound according to Item 5, wherein at least about 5% of the amino acids are lysine and / or arginine, and / or at least about 20% of the amino acids are lysine and / or arginine.
[0686] Item 7. A peptide-containing compound according to any one of the preceding items, wherein the peptide component is an antimicrobial peptide
[0687] and / or anti-inflammatory peptides, or fragments and / or minor variants of such peptides.
[0688] Item 8. A peptide-containing compound according to any one of the preceding items, wherein the amino acids in the peptide component
[0689] At least about 5% contain aromatic groups.
[0690] Item 9. A peptide-containing compound according to Item 8, wherein at least about 10% of the amino acids contain aromatic
[0691] Group.
[0692] Item 10. The peptide-containing compound according to Item 8 or Item 9, wherein the aromatic group-containing amino acid is selected from tyrosine and 3,4-dihydroxyphenylalanine.
[0693] Item 11. A peptide-containing compound according to any one of the preceding items, wherein the peptide component comprises mussel
[0694] One or more amino acid fragments / sequences of an Adhesion protein.
[0695] Item 12. The peptide-containing compound according to Item 11, wherein the mussel adhesive protein is mefp-1. Item 13. The peptide-containing compound according to any one of the preceding items, wherein the peptide component comprises the following
[0696] Amino acid sequence or consisting of:
[0697] X-Pro-YZ (SEQ ID No: 5),
[0698] in:
[0699] X represents a chain of 1 to 2 amino acid residues, each of which is independently selected from Ala and Lys;
[0700] Y is selected from Ser and pSer;
[0701] Z represents a chain of 1 to 7 amino acid residues, each of which is independently selected from Tyr, pTyr, 3Hyp or 4Hyp, Thr, pThr, DOPA and Lys; and
[0702] At least one of the Ala and / or Lys residues is bonded to one or more compounds of Formula I. Item 14. A peptide-containing compound according to any one of the preceding items, wherein the peptide component comprises the following
[0703] Amino acid sequence or consisting of:
[0704] G 1 -Lys-Pro-G 2 -T-Hyp-G 3 -Lys (SEQ ID No: 7),
[0705] in
[0706] G1 Ala does not exist or represent;
[0707] G 2 Selected from Ser and pSer;
[0708] T is selected from DOPA, Tyr and pTyr;
[0709] Hyp is selected from 3Hyp and 4Hyp;
[0710] G 3 represents a chain of 1 to 3 or 1 to 4 amino acid residues, each of which is independently selected from Tyr, pTyr, 3Hyp, 4Hyp, Thr, pThr and DOPA; and
[0711] At least one of said Lys residues and / or said Ala residue when present is bonded to at least one compound of formula I as defined in item 1.
[0712] Item 15. A peptide-containing compound according to Item 14, wherein the peptide component comprises the following amino acid sequence
[0713] or consisting of:
[0714] Lys-Pro-G 2 -T-Hyp-G 3 -Lys (SEQ ID No: 8),
[0715] Among them G 2 , T, Hyp and G 3 is defined in item 14.
[0716] Item 16. The peptide-containing compound according to Item 14, wherein G 1 Represents Ala.
[0717] Item 17. A peptide-containing compound according to Item 14 or 16 and any one thereof, wherein the peptide component comprises
[0718] Containing or consisting of the following amino acid sequence:
[0719] Ala-Lys-Pro-G 2 -T-Hyp-Hyp-Thr-G 4 -Lys (SEQ ID No: 9),
[0720] Among them G 2 , T and Hyp are defined according to item 14, and G 4 Selected from Tyr, pTyr, 3Hyp,
[0721] 4Hyp, Thr, pThr and DOPA.
[0722] Item 18. A peptide-containing compound according to any one of Items 14 to 17, wherein G 2 Stands for Ser.
[0723] Item 19. The peptide-containing compound according to any one of Items 14 to 18, wherein T represents Tyr.
[0724] Item 20. A peptide-containing compound according to any one of Items 14 to 19, wherein G 3 or G 4 (Depending on the situation
[0725] ) represents Tyr or DOPA.
[0726] Item 21. A peptide-containing compound according to Item 20, wherein the peptide component comprises the following amino acid sequence
[0727] or consisting of:
[0728] Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Lys (SEQ ID No: 4);
[0729] Ala-Lys-Pro-pSer-Tyr-Hyp-Hyp-Thr-DOPA-Lys (SEQ ID No: 11);
[0730] Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Lys (SEQ ID No: 12);
[0731] Ala-Lys-Pro-pSer-Tyr-Hyp-Hyp-Thr-Tyr-Lys (SEQ ID No: 13);
[0732] Lys-Pro-Ser-Tyr-Hyp-DOPA-Lys (SEQ ID No: 14); and
[0733] Lys-Pro-Ser-pTyr-Hyp-DOPA-Lys (SEQ ID No: 15).
[0734] Item 22. A peptide-containing compound according to Item 21, wherein the peptide component comprises the following amino acid sequence
[0735] or consisting of:
[0736] Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Lys (SEQ ID No: 12).
[0737] Item 23. A peptide-containing compound according to any one of Items 14 to 19, wherein G 3 (or G 4 , depending on the situation
[0738] Depends on) represents -V 1 -Thr-Tyr-V 2 -, where V 1 Bonded to Hyp and V 2 Bonded to Lys, and
[0739] V 1 and V 2 Independently, none, one or two Hyp groups are present.
[0740] Item 24. The peptide-containing compound according to Item 23, wherein -V 1 -Thr-Tyr-V 2 - represents -Hyp-Thr-Tyr-, -Hyp-Thr-Tyr-Hyp- or -Thr-Tyr-Hyp-.
[0741] Item 25. A peptide-containing compound according to Item 23, wherein the peptide component comprises the following amino acid sequence
[0742] or consisting of:
[0743] Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 18);
[0744] Ala-Lys-Pro-pSer-Tyr-Hyp-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 19);
[0745] Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 20);
[0746] Ala-Lys-Pro-pSer-Tyr-Hyp-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 21);
[0747] Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 22);
[0748] Ala-Lys-Pro-pSer-Tyr-Hyp-Thr-DOPA-Hyp-Lys (SEQ ID No: 23);
[0749] Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 24); and
[0750] Ala-Lys-Pro-pSer-Tyr-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 25).
[0751] Item 26. A peptide-containing compound according to Item 25, wherein the peptide component comprises the following amino acid sequence
[0752] or consisting of:
[0753] Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 24).
[0754] Item 27. A peptide-containing compound according to any one of the preceding items, wherein one or more compounds of Formula I
[0755] The conjugate is linked to the peptide component via one or more Ala or Lys moieties.
[0756] Item 28. A peptide-containing compound according to Item 27, wherein one or more compounds of Formula I are linked via an N-terminal Ala or Lys moiety and / or a C-terminal Lys moiety.
[0757] Item 29. A peptide-containing compound according to any one of the preceding items, wherein one or two compounds of Formula I
[0758] The compound is connected to the peptide component.
[0759] Item 30. A peptide-containing compound according to Item 29, wherein a compound of Formula I and the peptide component
[0760] connect.
[0761] Item 31. The peptide-containing compound according to Item 7, wherein the peptide component is cecropin or LL-37. Item 32. The peptide-containing compound according to Item 31, wherein the peptide component is cecropin A or cecropin B.
[0762] Item 33. A peptide-containing compound according to any one of the preceding items, wherein in the one or more compounds of Formula I, R 1 is selected from -C(CH3)2OH, -C(CH3)=CH2 and -C(CH3)2H; and / or n is 0.
[0763] Item 34. A peptide-containing compound according to any one of the preceding items, wherein the one or more compounds of formula I
[0764] The compound is montelukast, montelukast styrene, or hydrogenated montelukast styrene. Item 35. A peptide-containing compound as defined in any of the preceding items or a pharmaceutically or cosmetically acceptable
[0765] Acceptable salts are used as medicines.
[0766] Item 36. A pharmaceutical formulation comprising a compound as defined in any one of Items 1 to 34 or
[0767] Pharmaceutically or cosmetically acceptable salts thereof, and pharmaceutically or cosmetically acceptable adjuvants, diluents or carriers.
[0768] Item 37. A pharmaceutical formulation according to Item 36, which is suitable for, adapted to and / or packaged and presented for use
[0769] For external administration, wherein the pharmaceutically or cosmetically acceptable adjuvant, diluent or carrier is an external adjuvant, diluent or carrier.
[0770] Item 38. The formulation according to Item 36 or Item 37, which is in the form of a gel, spray, cream, ointment or
[0771] In dry powder form.
[0772] Item 39. A pharmaceutical formulation according to any one of Items 36 to 38, further comprising another anti-inflammatory agent. Item 40. A kit comprising the following components:
[0773] (A) a pharmaceutical formulation as defined in any one of items 36 to 38; and
[0774] (B) a pharmaceutical formulation comprising another anti-inflammatory agent in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier,
[0775] The components (A) and (B) are each provided in a form suitable for administration in combination with each other. Item 41. A compound as defined in any one of Items 1 to 34 or a pharmaceutically or cosmetically acceptable salt thereof, a formulation as defined in any one of Items 36 to 39, or a kit as defined in Item 40 for use in the treatment of inflammation, inflammatory disorders, and / or disorders characterized by inflammation.
[0776] Item 42. Use of a compound as defined in any one of items 1 to 34 or a pharmaceutically or cosmetically acceptable salt thereof, a formulation as described in any one of items 36 to 39, or a kit as described in claim 40 for the manufacture of a medicament for treating inflammation, inflammatory disorders, and / or disorders characterized by inflammation.
[0777] Item 43. A method of treating inflammation, an inflammatory disorder, and / or a disorder characterized by inflammation, wherein
[0778] The method comprises administering to a patient in need of such treatment a compound as defined in any one of items 1 to 34 or a pharmaceutically or cosmetically acceptable salt thereof, a formulation according to any one of items 37 to 39, or a kit according to item 40.
[0779] Item 44. A compound, formulation or kit for use according to Item 41, a use according to Item 42, or a method according to Item 43, wherein the inflammatory disorder is selected from psoriasis,
[0780] Acne, eczema, dermatitis, rhinitis, conjunctivitis, hemorrhoids, chronic obstructive pulmonary disease or inflammatory bowel disease. Item 45. The compound, formulation or kit for use according to Item 44, the use or
[0781] The method, wherein the disorder is chronic obstructive pulmonary disease.
[0782] Item 46. A compound, a formulation or a kit for use according to Item 44, wherein the compound, the formulation or the kit for use
[0783] The method, wherein the inflammatory bowel disease is ulcerative colitis.
[0784] Item 47. A compound, a formulation or a kit for use according to Item 44, wherein the compound, the formulation or the kit for use
[0785] The method, wherein the disorder is allergic rhinitis or allergic conjunctivitis.
[0786] Item 48. A compound, formulation or kit for use according to Item 41, a use according to Item 42, or a method according to Item 43, wherein the disorder characterized by inflammation is or results in a wound or burn.
[0787] Item 49. A compound, a formulation or a kit for use according to Item 48, wherein the compound, the formulation or the kit for use
[0788] The method, wherein the wound is an abrasion, scratch, cut, laceration, skin puncture, avulsion, bruise, scar or blister.
[0789] Item 50. A compound, a formulation or a kit for use according to Item 48, wherein the compound, the formulation or the kit for use
[0790] The method, wherein the disorder causing the wound is hemorrhoids or ulcerative colitis.
[0791] Item 51. A compound as defined in any one of Items 1 to 34 or a pharmaceutically or cosmetically acceptable salt thereof, or a formulation as defined in any one of Items 36 to 38, for use in the treatment of idiopathic pulmonary fibrosis.
[0792] Item 52. Use of a compound as defined in any one of Items 1 to 34 or a pharmaceutically or cosmetically acceptable salt thereof, or a formulation as defined in any one of Items 36 to 38 for the manufacture of a medicament for treating idiopathic pulmonary fibrosis.
[0793] Item 53. A method for treating idiopathic pulmonary fibrosis, the method comprising administering to a subject in need of such treatment
[0794] The patient is administered a compound as defined in any one of items 1 to 34, or a pharmaceutically or cosmetically acceptable salt thereof, or a formulation according to any one of items 36 to 38.
[0795] Item 54. A compound, a preparation or a test according to any one of Items 35 to 53 for use
[0796] A kit, use or method (as the case may be) wherein the one or more compounds or salts thereof are administered topically in the form of an external formulation.
[0797] Item 55. A compound, a formulation or a kit for use according to Item 54, wherein the compound, the formulation or the kit for use
[0798] A method wherein the condition of interest is treated by direct topical administration to the skin.
[0799] Item 56. A compound, a formulation or a kit for use according to Item 54, wherein the compound, the formulation or the kit for use
[0800] Methods wherein the relevant condition is treated by direct topical administration to a mucosal surface.
[0801] Item 57. A compound, a preparation or a test according to any one of Items 41 to 56 for use
[0802] Kit, use or method, as the case may be, wherein the compound or compounds are administered by oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular, intraperitoneal, pulmonary or anorectal delivery.
[0803] Item 58. A compound, a formulation or a kit for use according to Item 57, wherein the compound, the formulation or the kit for use
[0804] The method wherein the administration is via the lungs via a spray including a powder aerosol or a water mist for nebulization use.
[0805] Item 59. A compound, a formulation or a kit for use according to Item 58, wherein the compound, the formulation or the kit for use
[0806] The method wherein the spray is a liquid including an aqueous (aerosol) spray and the excipients may include one or more of a viscosity modifier, a sugar, an emulsifier, a buffer, an alcohol and a preservative.
[0807] Item 60. A compound, a formulation or a kit for use according to Item 58 or Item 59,
[0808] The use or method, wherein the administration is by an inhalation device selected from a pressurized metered dose inhaler, a dry powder inhaler, a soft mist inhaler or a nebulizer.
[0809] Item 61. A method for preparing a peptide-containing compound according to any one of Items 1 to 34, wherein
[0810] The method comprises reacting a compound of formula I as defined in any one of items 1, 35 or 36 with a compound of formula I as defined in item
[0811] The peptide component defined in any one of 1 to 26, 31 or 32 is reacted.
[0812] Item 62. A method for preparing a pharmaceutical formulation as defined in any one of Items 36 to 39,
[0813] The method comprises bringing into association a peptide-containing compound as defined in any one of items 1 to 34 with one or more pharmaceutically acceptable adjuvants, diluents or carriers.
[0814] Item 63. A method for preparing a kit as defined in Item 40, the method comprising associating component (A) of the kit with component (B) of the kit.
Claims
1. A peptide-containing compound selected from: Compound A: Montelukast styrene-Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Lys, which is Montelukast styrene covalently bonded to the amino acid SEQ ID No: 12 at the N-terminus; Compound B: Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Lys (Montelukast styrene), which is Montelukast styrene covalently bonded to the amino acid SEQ ID No: 4 at the C-terminus; Compound C: Montelukast styrene-Ala-Lys-Pro-pSer-Tyr-Hyp-Hyp-Thr-Tyr-Lys, which is Montelukast styrene covalently bonded to the amino acid SEQ ID No: 13 at the N-terminus; Compound D: Ala-Lys(Montelukast styrene)-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Lys(Montelukast styrene), which is two Montelukast styrene molecules covalently bonded to the amino acid SEQ ID No: 12 via a Lys residue; Compound E: Montelukast-Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Lys, which is montelukast covalently bonded to the amino acid SEQ ID No: 12 at the N-terminus; Compound F: hydrogenated montelukast styrene-Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Lys, which is hydrogenated montelukast styrene covalently bonded to the amino acid SEQ ID No: 12 at the N-terminus; Compound G: Montelukast-Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-Hyp-Lys, which is montelukast covalently bonded to the amino acid SEQ ID No: 24 at the N-terminus; Compound H: Montelukast styrene-Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-Hyp-Lys, which is montelukast styrene covalently bonded to the amino acid SEQ ID No: 24 at the N-terminus; or Compound J: Montelukast-Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Hyp-Lys, which is montelukast covalently bonded to the amino acid SEQ ID No: 20 at the N-terminus; in The amino acid sequences of SEQ ID No: 4, 12, 13, 20 and 24 are: Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Lys (SEQ ID No: 4); Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Lys (SEQ ID No: 12); Ala-Lys-Pro-pSer-Tyr-Hyp-Hyp-Thr-Tyr-Lys (SEQ ID No: 13); Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 20); and Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-Tyr-Hyp-Lys (SEQ ID No: 24); Montelukast has the following chemical structure: Montelukast styrene has the following chemical structure: Montelukast styrene hydrogenated has the following chemical structure: Or a pharmaceutically acceptable salt of the peptide-containing compound.
2. A pharmaceutical formulation comprising the peptide-containing compound according to claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adjuvant, diluent or carrier.
